Identification and Characterization of a Major Prostaglandin Glycerol Ester Hydrolase in Human Cancer Cells by Manna, Joseph Dominick
IDENTIFICATION AND CHARACTERIZATION OF A MAJOR PROSTAGLANDIN 
GLYCEROL ESTER HYDROLASE IN HUMAN CANCER CELLS  
 
By 
 
Joseph Dominick Manna 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements  
for the degree of 
DOCTOR OF PHILOSOPHY 
In 
Chemical and Physical Biology 
August, 2014 
Nashville, Tennessee 
 
 
Approved: 
H. Alex Brown. Ph.D 
Lawrence J. Marnett Ph.D 
Alan R. Brash Ph.D. 
Richard M. Caprioli Ph.D. 
Ned A. Porter Ph.D.
	  ii	  
DEDICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In loving memory of my grandmother, Filomena D’Orazio, who never gave up and 
taught us all to do the same.  She will always be an important part of me. 
 
 
To my family for supporting me in my life journey in science 
 
 
To my beloved fiancé, Febie, endlessly supportive and my personal cheerleader  
 
 
	  iii	  
ACKNOWLEDGEMENTS 
 
My time here at Vanderbilt was a long and difficult road full of many failures and 
successes.  Getting through the ups and downs would not have been so easy if it wasn't 
for the support and guidance of fellow researchers and friends. First, I have to thank my 
advisor, Professor Larry Marnett, for providing the guidance, encouragement, and 
willingness to provide me with all the resources I needed in my research and in my 
professional development.  His support has allowed me to become a more productive, 
enthusiastic, and independent scientist and I know my future is going to be full of fruitful 
adventures in research and life thanks to him.   
My scientific experience would not have been so successful if it wasn't for the 
help and guidance of a terrific committee.  I am particularly appreciative of Richard 
Caprioli for providing me with the training and resources to develop all the MALDI-MS 
techniques used throughout this work.  I am also appreciative of the guidance from my 
other committee members, Alex Brown, Alan Brash and Ned Porter. I was fortunate to 
have the opportunity to work with an remarkably knowledgeable and fun committee. 
I am thankful to numerous lab mates for their support and guidance.  Thanks to 
Chris Aluise , Jim Galligan and Will Beavers for providing a listening ear and helping me 
through many of the ups and downs of my research.  Thank you to Shu Xu for helping in 
the beginning of my purification struggles. Phil Kingsley answered countless questions 
and providing training regarding many LC-MS problems. James Wepy, who helped in the 
beginning of kinetic characterization and who will continue this work once I leave. Carol 
Rouzer has been a careful editor of much of my writing, and I have appreciated her 
advice throughout graduate school. Finally, a special thanks to Brenda Crews for running 
	  iv	  
a tight but always fun and enjoyable ship, and all of my lab mates for their positive 
attitudes and willingness to share knowledge. 
Thanks to Celeste Riley, Anne Lara, Mary Veazey and Stephen Doster who have 
provided valuable administrative support. They made everything easy; from getting time 
with Larry, scheduling rooms for practice talks or meetings, and helping with all my 
travel needs for courses and conferences.  They made everything easy so I didn't have to 
worry and could focus on research. 
Much the success would not have been possible if it was not for the willingness to 
share information, data, and resources of the Cravatt Lab at Scripps.  Thanks particularly 
to Professor Ben Cravatt for openly sharing all the ABPP data they have generated, for 
providing inhibitors for our biochemical research, and for a knowledgeable resource in 
everything related to serine hydrolases.   
 Working and training at Vanderbilt has allowed me to take advantage of 
numerous core resources to further my research and I am thankful for that.  The HTS 
Core provided me with the training, guidance, and instruments to develop our COX-2 
HTS screen.  The VAPR Core, particularly Erin Gribben, for all their help in protein 
expression in E.coli and for never getting aggravated whenever I came into their lab to 
ask for a new purification tag on my protein.   
My friends and family have made my time in Nashville some of the best years of 
my life. The times with friends out of the lab made the worst days in lab that much easier.  
I am thankful to my friends in Massachusetts and Nashville, for their support during 
graduate school, even though many now refuse to call me doctor now that it’s over.  
I am forever grateful for my parents who always supported me throughout my entire life 
	  v	  
and taught me never to give up no matter how difficult something may seem.  I have no 
doubt that these lessons gave me the drive and determination I needed to succeed in 
graduate school.  Finally I am eternally grateful to my fiancé, Febie.  She has been with 
me throughout every step of this process.  She has gotten me through the lows, when I 
felt nothing would work, and celebrated with me through the highs.  She made this entire 
process easier and I have our entire life to thank her for that.  
 
	  vi	  
TABLE	  OF	  CONTENTS	   	  Page	  	  DEDICATION	  ................................................................................................................................................	  ii	  	  ACKNOWLEDGEMENTS	  ........................................................................................................................	  iii	  	  LIST	  OF	  TABLES	  .........................................................................................................................................	  ix	  	  LIST	  OF	  FIGURES	  ........................................................................................................................................	  x	  	  LIST	  OF	  ABBREVIATIONS	  ...................................................................................................................	  xiii	  	  Chapter	  	  	  I	  .	  INTRODUCTION	  .....................................................................................................................................	  1	  	  
The Endocannabinoid System ......................................................................................... 1 
Overview ..................................................................................................................... 1 
Cannabinoid Receptors ............................................................................................... 2 
Biosynthesis and Metabolism of Endocannabinoids .................................................. 4 
Cyclooxygenase .............................................................................................................. 9 
Historical Overview .................................................................................................... 9 
Cyclooxygenase Biochemistry .................................................................................. 11 
Cyclooxygenase Catalytic Mechanism ..................................................................... 14 
Cyclooxygenase 1 versus Cyclooxygenase 2 ........................................................... 19 
COX-1 and COX-2 Structure and Substrate Binding - AA vs. 2-AG ...................... 19 
COX-2 Dependent Endocannabinoid Oxygenation .................................................. 22 
Physiology of Oxygenation Products of Endocannabinoids ..................................... 24 
Prostaglandin Glycerol Ester Hydrolytic Instability ................................................. 28 
Serine hydrolases .......................................................................................................... 29 
Overview ................................................................................................................... 29 
Ser-His-Asp Catalytic Triad ..................................................................................... 29 
Catalytic Mechanism of Serine Hydrolases .............................................................. 31 
Activity Based Protein Profiling ............................................................................... 34 
Applications of ABPP ............................................................................................... 36 
Dissertation Aims .......................................................................................................... 39 	  	  
	  vii	  
II.	  HIGH-­‐THROUGHPUT	  QUANTIFICATION	  OF	  BIOACTIVE	  LIPIDS	  BY	  	  	  	  	  	  	  MALDI	  MASS	  SPECTROMETRY:	  APPLICATION	  TO	  PROSTAGLANDINS	  ....................	  41	  	  
Introduction ................................................................................................................... 41 
Materials and Methods .................................................................................................. 43 
Results ........................................................................................................................... 48 
Method Development and Validation ....................................................................... 48 
COX-2 Inhibitor Assay: 14C-TLC or Oxygen Consumption vs.  
MALDI MS/MS ........................................................................................................ 52 
COX-2 Inhibitor Assay - High Throughput Screening (HTS)  
Method Development ................................................................................................ 53 
MALDI TOF analysis of Activated Macrophages .................................................... 55 
Discussion ..................................................................................................................... 57 
Supplemental Information ............................................................................................ 59 	  III.	  	  IDENTIFICATION	  OF	  A	  PROSTAGLANDIN	  GLYCEROL	  ESTER	  HYDROLASE	  	  IN	  MDA-­‐MB-­‐231	  CANCER	  CELLS	  BY	  PROTEIN	  PURIFICATION	  ................................	  60	  	  
Introduction ................................................................................................................... 60 
Materials and Methods .................................................................................................. 62 
Results ........................................................................................................................... 69 
Characterization of PGE2-G Hydrolysis in MDA-MB-231 Cancer Cells ................ 69 
Purification of unknown PG-G Serine Hydrolase .................................................... 70 
Characterization of PG-G binding by Competitive ABPP ....................................... 74 
Protein Identification and Validation ........................................................................ 75 
Discussion ..................................................................................................................... 80 	  IV.	  	  IDENTIFICATION	  OF	  THE	  MAJOR	  PROSTAGLANDIN	  GLYCEROL	  	  ESTER	  HYDROLASE	  IN	  HUMAN	  CANCER	  CELLS	  .............................................................	  82	  	  
Introduction ................................................................................................................... 82 
Lysophospholipases ...................................................................................................... 85 
Lysophospholipid Production, Recycling and Metabolism ...................................... 85 
Lysophospholipase A1 and A2 ................................................................................. 87 
Materials and Methods .................................................................................................. 91 
Results ........................................................................................................................... 98 
Characterization of PGE2-G Hydrolysis in Cancer Cells ......................................... 98 
LYPLA2 Involvement in PGE2-G Hydrolysis ........................................................ 100 
LYPLA1 Involvement in PGE2-G Hydrolysis ........................................................ 103 
Expression of Recombinant Human LYPLA1 and LYPLA2 ................................. 105 
Expression, Isolation, and Activity of Recombinant Human LYPLA2 .................. 106 
Lysophospholipids, Endocannabinoids, and Prostaglandin Glycerol  
Esters as Substrates of Recombinant LYPLA2: A Kinetic Analysis ...................... 107 
Inhibition of Recombinant LYPLA2 Results in Decreased Hydrolysis  
of PG-Gs ................................................................................................................. 110 
	  viii	  
LYPLA2 Inhibition Reduced PG-G Hydrolysis in RAW 264.7  
Murine Macrophage-Like Cells .............................................................................. 112 
LYPLA2 Inhibition Reduced PG-G Hydrolysis in 1483 Human  
Squamous Cell Carcinoma Cells ............................................................................ 114 
Discussion ................................................................................................................... 116 
Acknowledgements ..................................................................................................... 119 
Supplemental Information .......................................................................................... 120 	  V.	  	  SUMMARY	  .........................................................................................................................................	  122	  	  REFERENCES	  .........................................................................................................................................	  128	  
	  ix	  
LIST OF TABLES 	  
 
Table               Page 
 
III-1.  Purification Table of PG-G Hydrolase from MDA-MB-231 ............................... 73 
 
IV-1.  Kinetic parameters for hydrolysis of multiple lipid substrates by  
recombinant human LYPLA2 ............................................................................. 108 
 
 
	  x	  
 
LIST OF FIGURES 	  
	  
Figure                                        Page 
	  
I-1.  Structures of the endocannabinoids ........................................................................ 2 
 
I-2.  Biosynthesis pathway of AEA ................................................................................ 5 
 
I-3.  Biosynthesis pathway of 2-arachidonoyl glycerol .................................................. 8 
 
I-4.  Structure of Salicylic Acid and Aspirin ................................................................ 10 
 
I-5.  Structure of COX-2 ............................................................................................... 13 
 
I-6.  Products of Arachidonic Acid Oxidation by Cyclooxygenase ............................. 15 
 
I-7.  Branched Chain Mechanism of COX ................................................................... 16 
 
I-8.  Mechanism of Cyclooxygenase Catalysis ............................................................ 18 
 
I-9.  Crystal structures for AA and 1-AG binding to COX enzymes in  
the COX Active Site ............................................................................................. 21 
 
I-10. Endocannabinoid Oxidation by COX-2 ................................................................ 23 
 
I-11.  COX-2 at the interface of the eicosanoid and endocannabinoid systems ............. 27 
 
I-12. The Ser-His-Asp catalytic triad ............................................................................ 30 
 
I-13.  Catalytic Mechanism for Serine Hydrolases ......................................................... 33 
 
I-14.  Competitive ABPP ................................................................................................ 37 
 
II-1.  Conversion of AA and 2-AG to PGs and PG-Gs by COX-2 ................................ 42 
 
II-2.  MALDI mass spectra of PGE2, PGD2, PGE2-G, and 6-keto-PGF1α  
before and after derivatization with Girard’s T reagent ........................................ 50 
 
II-3.  Representation of standard curves for both PGE2 in solution alone  
and PGE2 in solution with PGE2-G. ...................................................................... 51 
 
II-4.  IC50 values for COX-2 inhibitor, indomethacin, determined by  
MALDI MS/MS; validation of Girard’s reagent T as quench .............................. 53 
 
	  xi	  
II-5.  IC50 values determined for COX-2 inhibitors using the high  
throughput assay ................................................................................................... 55 
 
II-6.   MALDI MS of media extracted from LPS-activated RAW cells ......................... 56 
 
III-1.  Scheme of Competitive ABPP .............................................................................. 65 
 
III-2.  PGE2-G hydrolase activities in MDA-MB-231 .................................................... 70 
 
III-3.  Elution and activity profiles for PG-G hydrolase purification .............................. 72 
 
III-4.  SDS-PAGE gel with Coomassie blue staining for each step in  
purification ............................................................................................................ 74 
 
III-5.  PGE2-G Competitive ABPP .................................................................................. 75 
 
III-6.  Known hydrolytic functions of PGLS, PAFAH1β3, and DDAH2 ....................... 77 
 
III-7.  PGLS, DDAH2 and PAFAH1β3 overexpression in HEK293 .............................. 78 
 
III-8.  PGLS and PAFAH1β3 siRNA knockdown in MDA-MB-231 cells .................... 79 
 
IV-1.  Biosynthesis and metabolism of 2-AG ................................................................. 83 
 
IV-2.  Lysophospholipid biosynthesis and processing .................................................... 87 
 
IV-3.  Crystal Structure of LYPLA1 ............................................................................... 90 
 
IV-4.  PGE2-G hydrolase activities in human cancer cells .............................................. 99 
 
IV-5.  LYPLA2 siRNA knockdown in MDA-MB-231 cells and LYPLA2 
overexpression in HEK293 ................................................................................. 102 
 
IV-6.  LYPLA1 and LYPLA2 siRNA knockdown in MDA-MB-231 cells. ................. 104 
 
IV-7.  LYPLA1 and LYPLA2 overexpression in HEK293 .......................................... 105 
 
IV-8.  Production of recombinant human LYPLA1 and LYPLA2 by  
overexpression in E.coli ...................................................................................... 106 
 
IV-9.  Production of recombinant his-tagged human LYPLA2 by  
overexpression in E.coli ...................................................................................... 107 
 
IV-10.  LYPLA2 hydrolytic activity against multiple lipid substrates ........................... 109 
 
IV-11.  Inhibition of LYPLA2 by small molecule inhibitors .......................................... 111 
	  xii	  
 
IV-12.  LYPLA2 inhibition significantly increases endogenous levels of  
PGE2-G/PGD2-G formed in RAW264.7 murine macrophage-like cells ............ 113 
 
IV-13.  LYPLA2 inhibition significantly increases endogenous levels of  
PGF2α-G formed in 1483 human squamous cell carcinomas .............................. 115 
 
IV-14.  LYPLA2 involvement in the hydrolysis of glycerol prostaglandins  
in the endocannabinoid metabolism network ..................................................... 118 
 
  
	  xiii	  
LIST OF ABBREVIATIONS 
 
 
2-AG    2-arachidonoylglycerol 
AA    arachidonic acid  
ABHD    α/β-hydrolase domain  
ABPP    activity based protein profiling  
ACN     acetonitrile 
AEA    N-arachidonoyl ethanolamide 
cAMP    cyclic AMP 
CB    cannabinoid receptor 
cDNA    circular deoxyribonucleic acid 
CES1    carboxylesterase 1 
CHCA    cyano-4-hydroxy-cinnamic acid 
CID    collision-induced dissociation 
COX    cyclooxygenases 
DDAH2   dimethylarginine dimethylaminohydrolase 2 
DAG     diacylglycerol 
DAGL    diacylglycerol lipase 
DMSO    dimethyl sulfoxide 
DTT    dithiothreitol 
-EA    ethanolamine 
EDTA    Ethylenediaminetetraacetic acid 
FAAH    fatty acid amide hydrolase 
FBS    fetal bovine serum 
	  xiv	  
FP    fluorophosphonate 
-G    glycerol 
GPCR     G-protein coupled receptor 
IC50     inhibitory concentration 50% 
IP3    inositol 1,4,5-triphosphate 
LC    liquid chromatography 
LOX    lipoxygenase 
LPS    lipopolysaccharide LPS 
LYPLA1   lysophopholipase A1 
LYPLA2   lysophopholipase A2 
LysoPL   lysophospholipids 
LysoPC   lysophosphatidylcholine 
LysoPE   lysophosphatidylethanolamine 
MAGL   monoacylglycerol lipase 
MALDI   Matrix Assisted Laser Desorption Ionization 
mRNA    micro ribonucleic acid 
MS    mass spectrometry 
MS/MS    tandem mass spectrometry 
MudPIT   multidimensional protein identification technology  
NAPE    N-arachidonoylphosphatidylethanolamine 
NSAID   non-steroidal anti-inflammatory drugs  
NAT    N-acyltranferase (NAT) 
PAFAH1β3   platelet activating factor acetylhydrolase 1β3 subunit 
	  xv	  
PAGE    polyacrylamide gel electrophoresis 
PE    phosphatidylethanolamine 
PG    prostaglandin 
PGHS    prostaglandin H2 synthases 
PGLS    6-phosphoglucolactonase 
PLA    phospholipase A 
PLC    phospholipase C 
PLD    phospholipase D 
POX    peroxidase 
PPT1    palmitoyl protein thioesterase 1 
-SA    serinol amide 
SDS    sodium dodecyl sulfate 
siRNA    small interfering ribonucleic acid 
SRM    selected reaction monitoring 
TAMRA   tetramethylrhodamine 
THC    Δ9-tetrahydrocannabinol 
TXA2     thromboxane A2 
WT     wild-type 
	  1	  
 
Chapter I  
 
 
 
INTRODUCTION 
 
 
The Endocannabinoid System 
Overview 
The endocannabinoid system is a lipid signaling system that derives its name from 
the Cannabis sativa plant, more commonly known as marijuana.  Cannabis sativa has 
been cultivated by humans for thousands of years and was predominantly used for fabric 
and binding.  Scientists and physicians became interested in Cannabis sativa when 
Napoleon’s troops returning from Egypt described the plants psychotropic effects (1).  
Medically, Cannabis sativa extracts began to be used for their analgesic and 
antispasmodic effects (2). Due to the psychotropic and analgesic effects of Cannabis 
sativa, modern applications have grown and include both medicinal and recreational uses. 
The physiological and psychotropic effects of Cannabis sativa are predominantly 
caused by the plant’s active component, the terpenoid derivative Δ9-tetrahydrocannabinol 
(THC).  Though the active agent was identified in the 1960s, it was not until the 1990s 
that the receptor activated by THC was identified in mammalian brain (3).  Soon after 
this cannabinoid receptor, named CB1, was identified, another receptor (CB2) was cloned 
through sequence homology (4).  Both receptors are expressed throughout the body with 
each being concentrated in specific locations. CB1 is expressed throughout the central 
nervous system, with highest expression in the basal ganglia, hippocampus, and 
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cerebellum, whereas CB2 is predominately expressed in the immune system. Receptor 
signaling plays a role in numerous biological processes including pain, motor function, 
cognition, food intake, body temperature, and inflammation. Following identification of 
the cannabinoid receptors, endogenously produced ligands were discovered.  These 
compounds, which are arachidonic acid derivatives, were termed endocannabindoids and 
included N-arachidonoyl ethanolamide (AEA), more commonly known as anandamide 
(5), and 2-arachidonoyl glycerol (2-AG) (Figure 1) (6). 
I-1. Structures of the endocannabinoids 
 
 
Figure 1: Structures of the endocannabinoids 
 
 
AEA was the first endocannabinoid identified in 1992 by a screen for endogenous ligand 
for the cannabinoid receptors.  Three years later, 2-AG was discovered and isolated from 
mammalian intestinal tissue. 
 
Cannabinoid Receptors 
  As mentioned above, there are two major G-protein coupled receptors for 
endocannabinoids, the CB1 and CB2 receptors.  The first receptor identified was named 
the CB1 receptor and is mainly present in nerve cells (central and peripheral neurons and 
glial cells) and reproductive system (7-10).  The CB2 receptor was initially found in the 
O
O
OH
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H
O
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immune system, with highest expression in B lymphocytes, moderate expression in 
monocytes and neutrophils, and lowest expression in T lymphocytes and microglial cells 
(1, 4, 11). Interestingly, CB receptors play an important role during development of the 
brain, where they control differentiation (12).  In adult brains, cannabinoid receptors 
(predominantly CB1) are the most abundant G-protein coupled receptors, with levels 10-
50 fold higher than other receptors, such as dopamine or opioid receptors (8, 9).    
 Both CB receptors are coupled to similar transduction networks, including GPCR 
coupled pathways, ion channel regulation and protein kinase pathways.  CB receptor 
GPCR pathway activation leads to either inhibition of cAMP through coupling to Gi 
proteins, resulting in decreased protein kinase A phosphorylation (7, 9), or stimulation of 
cAMP formation through coupling to the Gs proteins (13). Additionally, cannabinoid 
receptors can couple to ion channels and result in the inhibition of Ca2+ influx through 
interaction with multiple calcium channel types (N, P/Q, and L types, (14-16). This is 
related to endocannabinoid involvement in neurotransmitter release and synaptic 
plasticity (17, 18).  Furthermore, cannabinoid receptors couple to a multitude of protein 
kinase cascades, including mitogen-activate protein kinase, phosphatidylinositol 3-kinase, 
and focal adhesion kinase (19-21).   
 Endocannabinoids differ in how they bind the cannabinoid receptors.  AEA acts 
as a partial agonist at both receptors but has a higher affinity for the CB1 receptor, with 
activity at CB1 4-30 fold higher then at CB2 (21, 22).  In contrast, 2-AG is a complete 
agonist of both cannabinoid receptors though it exhibits lower affinity then AEA for 
either receptor (21, 23).  
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Biosynthesis and Metabolism of Endocannabinoids 
 
N-Arachidonoyl ethanolamine:  AEA is primarily synthesized from membrane 
phospholipids through a two-step process.  Initially, increased Ca2+ stimulates the N-
acylation of phosphatidylethanolamine (PE), where an acyl group is specifically 
transferred from the sn-1 position of a glycerophospholipids to the amine of PE, to form 
N-arachidonoylphosphatidylethanolamine (NAPE) (24-26).  The enzyme responsible for 
this transfer is N-acyltranferase (NAT) (24-26). The next step involves the hydrolysis of 
NAPE by a NAPE-phospholipase D (PLD) to produce AEA and phosphatidic acid 
(Figure 2) (24-26).  NAT is inactive in the absence of Ca2+, and increasing the 
concentrations of Ca2+ during synaptic transmission activates NAT (27). 
Alternative pathways for the production of AEA exist in cellular systems.  
Phospholipases (PLA1/A2) catalyze the hydrolysis of NAPEs to N-acyl-lysoPEs (Lyso-
NAPEs) (28, 29), which are further cleaved at the phosphodiester bond by a 
lysophospholipase D to generate AEA (Figure 2).  However, NAPE-PLD has low 
hydrolytic activity for lyso-NAPE, implying the role of another lysophospholipase (30). 
The serine hydrolase α/β-hydrolase domain 4 (ABHD4) has shown to accept a wide array 
of lyso-NAPEs, including ones containing arachidonoylethanolamine (31). Another 
alternative pathway for AEA biosynthesis was identified in macrophages, and involved 
the hydrolysis of NAPE to phosphoanandamide by phospholipase C, followed by 
dephosphorylation through a phosphatase to generate AEA. This pathway may account 
for findings showing anandamide tissue levels are unchanged in NAPE-PLD knockout 
mice (32).  
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I-2. Biosynthesis pathway of AEA 
 
Figure 2:  Biosynthesis pathway of AEA 
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Once AEA is synthesized in neurons, it passively diffuses through the 
postsynaptic membrane into the intracellular space where it can engage the cannabinoid 
receptors as well as catabolic enzymes (33).  Additionally, AEA is trafficked by specific 
transporters, which are modulated by levels of intracellular AEA (34).  Once in the cell, 
AEA is subject to hydrolysis, to form free arachidonic acid and ethanolamine.  The major 
enzyme responsible for this hydrolysis was identified as the serine hydrolase fatty acid 
amide hydrolase (FAAH) (35-38).  FAAH is an inter-cellular membrane-bound protein 
that hydrolyzes a wide array of ethanolamine containing lipids, including 
oleoylethanolamide (39) and palmitoylethanolamine (40, 41). Furthermore, AEA is 
subject to oxidative metabolic pathways; including lipoxygenases (LOXs), 
cyclooxygenases (COX-2) and cytochrome P450s (42). AEA oxidation by COX-2 results 
in the formation of ethanolamides of the prostaglandins, termed prostamides, which will 
be described in further detail below. 
 
2-Arachidonoyl glycerol:  Similar to AEA, the major pathways for the biosynthesis of 2-
arachidonoyl glycerol (2-AG) begins in the lipid bilayer.  Biochemical studies have 
indicated multiple pathways for the generation of 2-AG. Primarily, arachidonic acid 
containing inositol phospholipids are sequentially hydrolyzed by the serine hydrolases, 
phospholipase C (PLC) and diacylglycerol lipase (DAGL) (6, 43, 44).  In response to 
extracellular stimulation, increases in cellular calcium trigger PLCs to catalyze the 
hydrolysis of phosphatidylinositol-4-5-bisphosphate (Figure 3) to produce two well-
studied second messenger molecules, inositol 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG) (44-46).  Next, DAGL hydrolyzes DAG at the sn-1 position to produce 2-AG, 
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which is released from cells to stimulate the CB receptors. Alternatively, 2-AG can be 
produced by the action of phospholipase A1 (PLA1) and lysophosphotidylinositol specific 
phospholipase C (lysoPLC). PLA1 acting on inositol containing phospholipids generates 
the inositol-containing lysophospholipid (Figure 3) (6, 47, 48).  From here, a lysoPLC 
generates 2-AG by cleavage of the phosphoinositol containing head group.  Many of 
these biosynthetic pathways differ depending on stimulation conditions, e.g. calcium 
stimulation, receptor activation.   
  
	  8	  
 
 
  I-3. Biosynthesis pathway of 2-arachidonoyl glycerol 
 
 
Figure 3:  Biosynthesis pathway of 2-arachidonoyl glycerol  
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Similar to AEA, 2-AG signaling is terminated by enzymatic hydrolysis, 
generating arachidonic acid and glycerol (49).  Due to the structural similarities between 
AEA and 2-AG, it was hypothesized that FAAH also hydrolyzes 2-AG (50).  Though 
FAAH is capable of hydrolyzing 2-AG, it was determined that the major enzyme 
responsible for 2-AG metabolism is monoacylglycerol lipase (MAGL) (51). MAGL is 
abundantly expressed in the nervous system and localizes on neurons that express CB1 
receptors (52, 53).  Though MAGL accounts for ~85% of the degradation of 2-AG, the 
remaining 15% of 2-AG metabolism is attributed to two serine hydrolases, α/β hydrolase 
(ABHD) domain proteins, ABHD6 and ABHD12.  2-AG is also subject to oxidative 
metabolism by many of the same enzymes that oxygenate both arachidonic acid (AA) 
and AEA.  The remainder of this work will focus on COX-2 oxidation products of the 
endocannabinoids. 
 
Cyclooxygenase 
Historical Overview   
The history of cyclooxygenases is a long and fruitful one.  It begins in ancient 
times where people unknowingly manipulated the enzyme for the treatment of pain and 
inflammation.  The first examples of pain relief are mentioned in the Ebers papyrus 
which dates to 1500 BC where it is recommended to use myrtle leaves to relieve pain 
(54-56).  Hippocrates followed in 400 BC with his recommendations for the consumption 
of bark from the willow tree to alleviate fever and pain (54-56). In 1763, Edward Stone 
used willow bark to treat fevers in 50 of his patients, and was one of the first to 
scientifically publish the results (54, 57).  It wasn't until 1838 that Raffaelle Piria was 
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able to isolate and identify the active component of the willow bark as salicylic acid 
(Figure 4).  Twenty years later, Hammond Kolbe was the first to synthesize salicylic acid 
which eventually led to industrial scale up and production of the compound (56, 57). 
Though salicylic acid was a useful treatment for fever and pain, it had some 
undesirable qualities, including a bitter taste and irritability to both the mouth and 
stomach (55-57).  These undesirable qualities led Felix Hoffman in 1897 to synthesize an 
acetylated version of salicylic acid, mainly to help his father tolerate the drug better. The 
new compound, named aspirin (Figure 4), caused less dyspepsia than salicylic acid (55-
57).  Detailed pharmacological and toxicological tests confirmed the actions of aspirin as 
an excellent analgesic and antipyretic (56-58). It would take another 70 years to identify 
prostaglandin H2 synthases (PGHS), also known as cyclooxygenases (COX), as the 
targets for these newly developed non-steroidal anti-inflammatory drugs (NSAIDs) (56, 
57, 59). 
  I-4. Structure of Salicylic Acid and Aspirin 
          
         Salicylic Acid                      Aspirin 
Figure 4: Structure of Salicylic Acid and Aspirin 
 
With the mass production, commercialization and administration of aspirin as a 
drug, scientists began to study what effect this compound was having in the body.  It was 
first shown in 1971 by Sir John Vane that aspirin, and other newly developed NSAIDs, 
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inhibited the synthesis of prostaglandins in guinea pig lungs (59).  He concluded that the 
effects of NSAIDs were due to decreased production of prostaglandins by inhibition of 
COX.  Smith and Willis’s findings on the effect of aspirin on platelet behavior was 
published jointly with Vane’s (60).  They showed that platelets isolated from patients 
treated with aspirin were not able to aggregate, and produced lower levels of 
prostaglandins as compared to controls (58, 60). The effects of NSAIDs as a whole were 
due to inhibition of prostaglandin formation by COX, causing positive effects such as 
anti-inflammatory, analgesic and anti-pyretic responses; but also many of the side effects, 
including damage to stomach mucosa and the gastrointestinal system and kidney toxicity 
(58). 
 
Cyclooxygenase Biochemistry 
Cyclooxygenases (COXs) are membrane bound homodimeric proteins comprised 
of 70 kDa monomers.  Each monomer of the protein contains both a cyclooxygenase 
active site and a peroxidase active site, and requires heme to catalyze its reactions (61-
64).  Structurally, COXs are homodimer proteins composed of tightly associated 
monomers with each protein consisting of three distinct regions; an epidermal growth 
factor domain near the dimer interface, a membrane binding domain which binds 
monotopically to the lipid bilayer, predominantly at the endoplasmic reticulum, and the 
catalytic domain, which possesses both a cyclooxygenase (COX) and a peroxidase (POX) 
functionality (Figure 5) (61-64).  Monomers of COX differ in terms of activity, with 
maximal COX activity occurring when one molecule of heme is bound per dimer of 
protein (65). These leads to a protein that has one catalytically active subunit and one 
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non-catalytically active subunit that acts as an allosteric modulator of the catalytic 
subunit. Additionally, some NSAIDs, such as indomethacin, are able to inhibit COX at a 
stoichiometric ratio of one NSAID for each dimer (66). Multiple studies utilizing various 
fatty acids and COX inhibitors have shown that COX is a structural homodimer but a 
functional heterodimers during catalysis and inhibition (67-70). 
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I-5. Structure of COX-2 
 
 
Figure 5:  Structure of COX-2:  Homodimer with the membrane-binding domain is in 
blue, EGF-like domain is in green and the catalytic domain in grey.  The heme is shown 
(red) bound in the POX active site  (PDB ID: 3PGH) 
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Cyclooxygenase Catalytic Mechanism   
Cyclooxygenases are bi-functional enzymes that perform consecutive reactions in 
two active sites, the COX and POX active sites (61, 62, 64, 71).  The bis-dioxygenation 
of arachidonic acid (AA) takes place in the L-shaped cavity of the COX active site, 
resulting in the production of prostaglandin G2 (PGG2).  PGG2 diffuses from the COX 
active site and is reduced in the POX active site to form PGH2.  Once produced, PGH2 is 
further processed by various synthases to form a wide array of prostaglandins and 
thromboxanes (Figure 6) (61, 62, 64, 71). 
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I-6. Products of Arachidonic Acid Oxidation by Cyclooxygenase 
 
Figure 6:  Products of Arachidonic Acid Oxidation by Cyclooxygenase 
 
Importantly, initiation of the COX reaction is dependent upon a two-electron oxidation of 
the heme present in the POX active site.  The need for heme oxidation in the 
cyclooxygenase enzyme is best described by the branched-chain mechanism (Figure 7), 
where the POX active site can function independently of the COX active site. 
Conversely, COX activity requires a two-electron oxidation of the POX active site 
protoporphyrin heme [(PPIX)Fe3+] in combination with a two-electron reduction of a 
hydroperoxide substrate, to form a ferryloxo protoporphyrin radical cation 
((PPIX )+Fe4+O). It is this protoporphyrin radical that initiates the COX active site by 
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radical abstraction of the hydrogen from Tyr-385 in the COX active site, leading to 
formation of a tyrosyl radical and initiation of the cyclooxygenase reaction (62, 64). 
I-7. Branched Chain Mechanism of COX 
 
Figure 7: Branched Chain Mechanism of COX (62). 
 
Once activated, the COX enzyme activity is initiated with the introduction of AA into the 
correct catalytic orientation in the COX active site (71).  This involves the placement of 
the carboxylic acid group of AA near Arg-120 and Tyr-355 at the opening of the binding 
pocket.  This orients the fatty acid chain of AA in the hydrophobic groove of COX, 
which orients carbon-13 below the catalytic Tyr-385 radical (Figure 8). This catalytic 
Tyr-385 radical can abstract the 13-proS-hydrogen of AA forming a carbon-centered 
radical.  Formation of this radical leads to a series of radical rearrangements along the 
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AA backbone, allowing the addition of two molecules of oxygen and formation of the 15-
hydroperoxyl radical of PGG2, with is reduced by Tyr-385 regenerating the radical Tyr-
385.  PGG2 migrates to the POX active site to be reduced to PGH2 (61, 62, 64, 71). 
	  18	  
I-8. Mechanism of Cyclooxygenase Catalysis 
 
Figure 8:  Mechanism of Cyclooxygenase Catalysis.  Substrate binding in the COX 
active site results in radical abstraction of the 13-proS-hydrogen of AA (A).  (B) The 
resulting oxygen radical shifts to the 11 position (C) which is then subject to addition of 
molecular oxygen (D).  Following addition of oxygen, the endoperoxide is formed 
between carbons 9 and 11 (E) followed by the formation of a single carbon-carbon bond 
between carbons 8 and 12 (F).  From here the radical shifts from carbon 13 to carbon 15 
(G), which is subject to another addition of molecular oxygen to form the peroxyl radical 
(H).  This radical is reduced by Tyr-385 to form PGG2 (I) and regeneration of the radical 
Tyr-385.  PGG2 migrates to the POX active site to be reduced to PGH2 (J) 
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Cyclooxygenase 1 versus Cyclooxygenase 2 
Though Vane described the cyclooxygenase enzymes as the target for aspirin; the 
discovery of two COX isoforms wasn't made until 1990 (72). The two enzymes (named 
COX-1 and COX-2) share 60% sequence identity and metabolize AA at the same rate 
(63).  COX-1, the first isoform discovered, is a constitutively expressed protein that is 
thought to maintain the homeostatic levels of prostaglandins throughout the body (73).  
COX-2 is the inducible form of the enzyme and its expression is triggered by multiple 
stimuli; including inflammatory cytokines, growth factors, and tumor promoters (73).   
The inducible nature of COX-2 has led many to believe the enzyme is responsible for 
prostaglandin formation during pathological states, including inflammation and 
tumorigenesis (73, 74). 
In addition to expression differences, both enzymes have differential binding for a 
wide array of substrates.  COX-1 is more selective in which substrates it utilizes and 
requires a free carboxyl group in fatty acid substrates in order to perform catalysis.  
COX-2 has been shown to possess more flexibility in which substrates bind to the active 
site.  As stated earlier, in addition to AA binding, COX-2 is also capable of metabolizing 
the endocannabinoids (75-77). Purified COX-2 can bind and oxygenate AEA and 2-AG 
while COX-1 has much reduced activity (75-77)  
 
COX-1 and COX-2 Structure and Substrate Binding - AA vs. 2-AG   
Exploration into why COX-2 can bind a wide array of substrates while COX-1 is 
more restricted led to structural investigations of both enzymes bound to AA and 1-AG 
(major form of 2-AG at equilibrium).  As mentioned previously, in both COX isoforms, 
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productive AA binding orients the ω-fatty acid tail into the top of the COX active site 
with the carboxylic acid group placed near the opening of the active site, known as the 
constriction site (63, 78), which positions the 13-proS-hydrogen of AA for radical 
extraction by Tyr-385 (Figure 10). 
1-AG binding to COX-2 is similar to that of AA, with the ω-fatty acid tail of 1-
AG placed in the hydrophobic binding pocket of COX-2 with the 13-proS-hydrogen 
oriented close to Tyr-385 (Figure 10) (79).  The difference in substrate binding lies near 
the constriction site. To facilitate the glycerol group of 1-AG, a leucine-531 residue must 
flip out of the binding pocket.  This creates the space necessary to bind 1-AG. Finally, the 
only hydrophilic interaction between 1-AG and COX-2 is between Tyr-355 and the 
carboxyl oxygen of 1-AG (79). 
Unlike COX-2, COX-1 is not able to effectively metabolize the 
endocannabinoids. For AA to be turned over by COX-1, the substrate must form 
hydrogen bonds between the carboxyl group of AA and Tyr-355 and Arg-120 at the 
constriction site (63, 80).  The position of Arg-120 is stabilized by interactions with Leu-
531 (78, 80).  With a lack of flexibility of Leu-531, the COX active site of COX-1 does 
not possess the volume necessary to accommodate larger substrates, including 2-AG and 
AEA (79). In COX-2, mutating the side chain of Leu-531 to alanine, phenylalanine, 
proline or threonine does not change substrate binding or decrease activity caused by a 
lack of Leu-531 and Arg-120 interaction, suggesting that Arg-120 binding in COX-2 is 
independent of Leu-531 involvement (79). 
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I-9. Crystal structures for AA and 1-AG binding to COX enzymes in the COX Active Site 
 
Figure 9:  Crystal structures for AA and 1-AG binding to COX enzymes in the COX 
Active Site.  A) Arachidonic acid binding to COX-1.  The orientation of AA (yellow) 
places the carboxylate at the constriction site, with hydrogen bonding (orange) to both 
Tyr-355 and Arg 120 (blue).  This places the 13-proS-hydrogen below Tyr-385 for 
radical extraction.  B) AA binding to COX-2.  AA (cyan) orients in the binding pocket 
similarly to COX-1 with the exception of missing hydrogen bond between Arg-120 
(green) and the carboxylate. C) 1-AG binding to COX-2.  Similar to AA, the 13-proS-
hydrogen of 1-AG (blue) is positioned close to Tyr-385 (green) for hydrogen extraction.  
At the constriction site, Leu-531 inverts its orientation compared to AA binding in order 
to accommodate the glycerol group of 1-AG.
	  22	  
COX-2 Dependent Endocannabinoid Oxygenation   
As mentioned previously, endocannabinoids are also substrates for cyclooxygenase.  Yu 
et al. presented the first evidence of COX-mediated metabolism of endocannabinoids in 
1997.  They showed that COX-2, but not COX-1, metabolized AEA at a rate of oxidation 
comparable to arachidonic acid, but with a 4-fold higher Km value for AEA (75).  The 
products of AEA metabolism are similar to the products produced from AA, with the 
major products being PGH2-EA, which is a substrate for the prostaglandin synthases, 
leading to production of a wide array of prostaglandin ethanolamide derivatives (81).  
However, unlike AA derived PGH2, PGH2-EA is a poor substrate for the thromboxane 
synthases (Figure 9) (77). 
The rate of oxygenation of 2-AG by COX-2 is as efficient as AA oxygenation 
(42, 76).  The products of 2-AG oxidation are virtually the same prostaglandin 
derivatives as those generated from AA, termed prostaglandin glycerol esters (PG-Gs). 
Similarly to PGH2-EA, PGH2-G is a poor substrate for thromboxane A2 and only the 
products of prostaglandin synthases are made (Figure 9).  Furthermore, 2-AG is a poor 
substrate for oxygenation by COX-1. 
The physiological actions of PG-Gs are of growing interest because they have 
been shown to activate calcium mobilization in macrophages and tumor cells, modulate 
synaptic transmissions, and induce hyperalgesia (82-86). Investigation into the 
physiological relevance of these COX-2 products has been difficult because of instability 
in biological fluids due to an active, unique, and unidentified serine hydrolase (87).  The 
identity of this hydrolase will be further examined later in this work.
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I-10. Endocannabinoid Oxidation by COX-2 
 
Figure 10: Endocannabinoid Oxidation by COX-2
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Physiology of Oxygenation Products of Endocannabinoids   
There is a growing interest in understanding the roles endocannabinoid derived 
COX-2 products play in physiological and pathophysiological settings. The first insights 
into the effects of these molecules came from the study of the synthetic PGF2α-EA 
analog, bimatoprost, and its use as an ocular hypotensive agent in the treatment of 
glaucoma and ocular hypertension (88). Bimatoproast and PGF2α-EA exert the same 
effect on intraocular pressure as PGF2α, however the fact that antagonists can block the 
effects of PGF2α-EA while having no effect on PGF2α suggests a specific receptor for 
PGF2α-EA.  This receptor was identified as a heterodimer of the FP receptor, comprised 
of one wild type FP receptor and one splice variant of the FP receptor with a shortened C-
terminus (88). 
PGF2α-EA has also been implicated in the process of inflammation.  In rat 
inflammatory pain models, PGF2α-EA levels in the spine were significantly increased and 
showed a pro-algesic effect.  COX inhibition in this model caused a decrease in PGF2α-
EA levels upon stimulation (89). However, not all prostamides elicit negative responses 
during inflammation.  PGE2-EA has been reported to reduce the expression of IL-12p40 
in activated macrophages and microglial cells, which leads to a reduction of the 
cytokines, IL-12 and IL-23 (90).  PGE2-EA also reduces the effects of lipopolysaccharide 
(LPS)-induced tumor necrosis factor (TNF-α) in whole blood and monocytes (91).  All 
these effects are predominately elicited through the binding of PGE2-EA to the EP2 
receptor.  Additionally, it appears that PGE2-EA binds to all the EP receptors (92). 
In addition to the prostamides, PG-Gs have also shown a wide array of 
physiological responses. In RAW264.7 murine macrophages, PGE2-G caused an increase 
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in Ca2+ mobilization that was independent of any known prostaglandin receptors.  This 
increase triggered the synthesis of IP3, activation of PKC, which leads to ERK 
phosphorylation. (82, 86).  These effects of PGE2-G were also mimicked in human non-
small cell lung carcinoma cancer cell line, H1819, where administration of the substrate 
triggered the same Ca2+ mobilization (86).  This increase in Ca2+ and increase in IP3 
production suggests the existence of PGE2-G-specific G-protein coupled receptors. 
Additionally, PGE2-G can induce hyperalgesia and modulate NF-κB activation in 
carrageenan-induced inflammation in the rat hind paw (85), as well as induce 
proinflammatory and neurotoxic effects in a rat model for Huntington’s disease (93). 
PGE2-G and PGF2α-G also increase LPS-induced inflammation in macrophage activation.  
Interestingly, not all PG-Gs are proinflammatory.  Specifically, PGD2-G reduces 
macrophage activation and exerts anti-inflammatory effects in LPS-induced inflammation 
in mice (72).  Also, the PGD2-G metabolite 15-deoxy-Δ12,14 prostaglandin J2-glycerol 
ester demonstrated PPAR-γ activation and reduction in T cell activation (94, 95). 
In neuronal cells, PG-Gs were able to modulate GABAergic receptor-mediated 
inhibition of synaptic transmission.  Specifically, PGE2-G was able to increase the 
frequency of miniature inhibitory postsynaptic currents, which was independent of the 
CB receptors (84). Other prostaglandin glycerol esters and amides (specifically PGD2-G, 
PGF2a-G and PGD2-EA) were also able to increase these frequencies while being 
mediated through novel receptors (84). Additionally, PGE2-G enhanced excitatory 
glutamatergic synaptic transmission, which was independent of the CB receptors in 
hippocampal neuron cultures (83).  Specifically, these prostaglandin glycerol esters 
induced injury, apoptosis and potentiated N-methyl-D-Aspartate (NMDA)-receptor 
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induced cell death, which is reversible by NMDA receptor antagonists, signifying 
neurodegeneration is due to the increased release of glutamate (83, 96). 
Figure 11 shows a full summary of the COX-2 oxidative metabolism of 
arachidonic acid and endocannabinoids. Injury or stimulation causes an elevation in 
COX-2 expression and activity, which oxygenates AA, 2-AG and AEA to produce PGs, 
PG-Gs, and PG-EAs, respectively. As stated above, endocannabinoids activate CB 
receptors while COX-2 oxidative metabolites of 2-AG or AEA exert their role in 
modulating activity through novel, unidentified receptors (83, 84).  Upon activation of 
these receptors, a number of different physiological effects occur, including many pro-
inflammatory or anti-inflammatory responses. 
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I-11. COX-2 at the interface of the eicosanoid and endocannabinoid systems 
 
 
Figure 11:  COX-2 at the interface of the eicosanoid and endocannabinoid systems. 
Enzymes responsible for 2-AG hydrolysis into AA and glycerol are mainly 
monoacylglycerol lipase (MAGL) and α/β hydrolase domain 6 (ABHD6). Fatty acid 
amide hydrolase (FAAH) hydrolyzes AEA into AA and ethanolamine. AA is metabolized 
by cyclooxygenases (COX-1/2) to give PGH2, which is taken up by specific PG synthases 
to produce the PGs (PGD2, PGE2, PGF 2α, PGI2) or thromboxane synthase to from 
thromboxanes (TXA2). PGs act through specific G protein-coupled receptors. During 
inflammation, COX-2 is upregulated leading to increased formation of PGs. Additionally, 
2-AG and AEA can be metabolized by COX-2 to form PG-glycerol esters (PG-Gs) and 
PG-ethanolamides (PG-EAs), respectively. The molecular targets of PG-Gs and PG-EAs 
are not well known. However, it is known that PGE2-EA is a ligand of the EP receptors, 
whereas PGF2α-EA activates a heterodimer of the FP receptor and one of its splicing 
variants. Abbreviations: DP, PGD2 receptor; EP, PGE2 receptor; FP, PGF2α receptor; IP, 
PGI2 receptor; TP, TXA2 receptor.
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Prostaglandin Glycerol Ester Hydrolytic Instability  
As stated previously, PG-Gs elicit a wide array of biological responses in predominantly 
an in vitro setting.  However, understanding the in vivo effects of these lipid metabolites 
has been difficult due to hydrolytic instability.  Vila et.al. demonstrated that PGE2-G is 
rapidly cleared from rat plasma post intravenous administration, with no detectable levels 
after 5 minutes. They attributed this instability to the presence of rat plasma esterases that 
hydrolyze the glycerol moiety of PG-Gs. The endocannabinoid hydrolyzing enzymes, 
FAAH and MAGL, were initially investigated as the responsible PG-G hydrolyzing 
enzymes (97).  However, kinetic analysis of both enzymes showed that neither FAAH 
nor MAGL contributed to the hydrolysis of PG-Gs.  
Further investigation let to the identification of carboxylesterase 1 (CES1) as an 
esterase capable of hydrolyzing PG-Gs, as well as the endocannabinoid, 2-AG (98).  It 
was shown that CES1 was responsible for 40-50% of 2-AG hydrolysis and 80-95% of 
PG-G hydrolysis in THP1 human macrophages (98).  Additionally, palmitoyl protein 
thioesterase 1 (PPT1) was identified as a PG-G hydrolyzing enzyme (99).  Similar to 
CES1, PPT1 was able to hydrolyze both 2-AG and PG-Gs, though PPT1 was more 
efficient at hydrolyzing 2-AG (Kcat/Km= 0.093 min-1 µM-1) compared to PG-Gs (Kcat/Km= 
0.021 min-1 µM-1). Beyond CES1 and PPT1, there is evidence to suggest the presence of 
other enzymes responsible for PG-G hydrolysis.  These unknown enzymes will be 
discussed in depth later in this work.   
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Serine hydrolases 
Overview  
Serine hydrolases are one of the largest and most widely distributed enzyme 
classes and constitute ~1% of the proteome (100, 101).  Serine hydrolases make up many 
of the proteases, esterases, lipases and amidises and can be organized into several distinct 
subfamilies based on three-dimensional structure and catalytic mechanism.  The majority 
of serine hydrolases adopt the α/β-hydrolase fold and employ a conserved catalytic 
mechanism, which involves nucleophilic attack by an activated serine, which is 
embedded in the serine hydrolase consensus sequence, GXSXG, within the active site 
(101). Enhanced nucleophilicity of the serine arises from interactions in either a catalytic 
triad or dyad.  The most common triad, present in most metabolic serine hydrolases, 
consists of a Ser-His-Asp triad, and allows for charge relay between the three residues. 
This triad will be discussed at length below. Other serine hydrolases utilize other triad 
combinations (Ser-Ser-Lys) or employ a dyad (Ser-Asp) (102, 103).  In every case there 
is a basic residue, which extracts a proton from the hydroxyl of serine to increase the 
nucleophilicity of serine for attack of carboxylates in varies substrates, including proteins 
and lipids.   
 
Ser-His-Asp Catalytic Triad   
The first serine hydrolase catalytic site was discovered in the 1960s by David 
Blow et. al. upon investigation of the crystal structure of the serine protease, α-
chymotrypsin (104).  They observed two amino acid residues that were directly involved 
in the catalytic mechanism of the enzyme, serine and histidine (104).   They showed that 
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the Ser and His residues resided close enough to form a hydrogen bond.  Additionally, 
they observed the presence of aspartate residue hydrogen-bonded to the His in the 
catalytic site.  The interaction of these three amino acids was dubbed the Ser-His-Asp 
catalytic triad (Figure 12).  The importance of this catalytic triad was revealed when other 
protease structures, including trypsin and subtilisin, also contained this same catalytic 
triad.  Interestingly, this catalytic triad exists in multiple hydrolase families, including 
proteases, esterases, and lipases, suggesting there is an independent evolutionary path for 
the formation of this important catalytic triad (105).  
I-12. The Ser-His-Asp catalytic triad 
 
Figure 12:  The Ser-His-Asp catalytic triad.  Hydrogen bonding network between the 
three amino acids created the charged relay system 
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(e.g. 2-AG, AEA). The role of Asp in this process was originally suggested to accept 
hydrogen upon removal from Ser, though it was shown that proton relay from the Ser to 
the Asp is chemically unstable (104-106).  Evidence suggests that hydrogen bonding 
between the Asp and His is important during catalysis, where Asp maintains orientation 
of the His and stabilizes the ion pairing between the negatively charged tetrahedral 
intermediate at Ser and the positively charged nitrogen of the His imidazole.  
Interestingly, mutagenesis studies that replace the catalytic Asp with a neutral 
amino acid resulted in significant decreases in catalysis, supporting the role of Asp in 
orienting and stabilizing the His imidazole ion during catalysis (105). Additionally, the 
role of Ser and His during catalysis is extremely important, with any mutations of serine 
or histidine destroying catalytic activity (107, 108).  This is not surprising because of the 
importance of both residues during catalysis, with the serine forming the acyl-enzyme 
intermediate and histidine transferring a proton from the serine to the substrate-leaving 
group.  All these mutagenesis studies highlight the importance of each residue in the 
catalytic mechanism of serine hydrolases.   
 
Catalytic Mechanism of Serine Hydrolases  
Serine hydrolases all share a common catalytic mechanism, which involves 
nucleophilic attack of an activated serine within the active site of these enzymes (108).  
The enhanced nucleophilicity of the active site serine arises from the amino acid’s 
interaction in a catalytic triad.  Figure 13 shows the basic mechanism of catalysis by a 
lipid serine hydrolase, utilizing a Ser-His-Asp triad. Generally, nucleophilic attack by the 
serine hydroxyl group at the carbonyl carbon atom of a substrate is catalyzed by proton 
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transfer from the serine to the histidine imidazole group acting as a general base.  This 
forms a tetrahedral intermediate of serine bound to substrate and an imidazole ion.  The 
tetrahedral intermediate breaks down by acid catalysis to form the acyl bound serine, a 
basic imidazole, and the liberated alcohol or amine product (depending on substrate i.e. 
fatty acid or protein).  The proton on the imidazole is transferred to the leaving product 
during this elimination.  The acyl-serine is deacylated though proton extraction of water 
by the imidazole base, generating a newly formed imidazole ion and attack of the newly 
formed hydroxyl base at the carbon of the acyl group.  This second tetrahedral 
intermediate breaks down through the same acid catalysis as before, to generate the 
hydroxylated substrate, and regenerate the serine and imidazole base for another round of 
hydrolysis (105).  
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I-13. Catalytic Mechanism for Serine Hydrolases 
 
Figure 13:  Catalytic Mechanism for Serine Hydrolases.  (A) Nucleophilic attack by 
an activated serine leads to the formation of a serine tetrahedral intermediate.  (B) The 
intermediate breaks down through acid catalysis to form the acyl serine intermediate and 
an alcohol product.  (C) The serine is deacylated by proton extraction of water followed 
by nucleophilic attack of the generated hydroxyl.  (D) This tetrahedral intermediate 
breaks down by acid catalysis to form (E) the free hydroxylated substrate and 
regeneration of serine and histidine. 
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Activity Based Protein Profiling   
Serine hydrolases are an important enzyme class that are involved in numerous 
physiological; including inflammation, angiogenesis, hormone processing (109-111), and 
pathophysiological events; including cancer, emphysema and blood clotting disorders 
(112-114).  As stated before, the class of serine hydrolases is expansive and 
understanding these enzymes’ roles and functions in many of these pathogenic states may 
help in future treatments.  Many of the serine hydrolases identified are completely 
uncharacterized with respect to their physiological functions making studying their 
physiological relevance difficult (114).  Because all serine hydrolases utilize a similar 
catalytic mechanism, developing probes that can covalently interact with the activated 
serine of these enzymes has allowed for functional characterization, including substrate 
identification and physiological relevance of many of these uncharacterized proteins.  
Activity based protein profiling (ABPP) emerged as a technology that took advantage of 
the conserved catalytic mechanism of serine hydrolases (114, 115).  
In general, the fundamental building blocks of ABPP are small-molecule probes 
that covalently label active site residues of a given enzyme class; including cysteine, 
serine, threonine hydrolases.  The remainder of this work will focus on the serine 
hydrolases. Ideal probes target a large number of different enzymes within the serine 
hydrolase family by targeting the conserved catalytic mechanism.  The serine hydrolase 
probes consist of electrophilic groups that modify the conserved active serine nucleophile 
leading to covalent tagging of the protein (115). These probes must also have a reporter 
tag allowing for visualization of targets. Reporter tags can range and include 
fluorophores, biotin and handles such as azides or alkynes with can be modified by click 
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chemistry [copper-catalyzed Huisgen’s cycloaddition].  Unique to ABPP is the ability to 
assess the functional states of known and unknown enzymes within a proteome, due to 
the probes interaction with enzymatically active proteins only. Utilizing these probes 
allows for proteome wide comparisons of enzyme activity in a number of distinct 
biological states, e.g. healthy versus disease or untreated versus treated. 
Historically, these probes were initially designed by protein chemists and 
enzymologists to try to understand mechanistic and structural characteristics of enzymes, 
and chemists utilized probes ranging from simple organic molecules to mechanism–based 
inhibitors. The work of Balls and Jensen in the 1950s on the stoichiometric inhibition of 
multiple serine proteases (trypsin, α-chymotrypsin, and cholinesterase) by the diisopropyl 
fluorophosphonate demonstrated irreversible inhibition by these compounds, which 
would become important for fluorophosphonate probe design in future ABPP work (116, 
117). Additionally, in the 1970s, Tipper and Strominger proposed the β-lactam of 
penicillin was a structural analog of the D-ala-D-ala end of bacterial peptidoglycan and 
that the β-lactam covalently interacted with the catalytic serine of bacterial 
transpeptidases, the enzymes responsible for cell wall biosynthesis (118).  Utilizing 
radiolabeled penicillin led to the identification of multiple binding partners for penicillin.   
They linked enzyme class function to biological function in determining specific 
enzymes involved in cell wall biosynthesis (119, 120). Much of this early work laid the 
foundation for later researchers to develop activity-based probes for multiple enzyme 
classes.  In the case of serine hydrolases, many types of electrophile probes have been 
developed, including fluorophosphonates, aryl phosphonates, sulfonyl fluorides, and 
carbamates.  Applications for ABPP will be discussed below. 
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Applications of ABPP 
ABPP has been used to profile activity of serine hydrolases in a multitude of 
biological setting, including cancer, nervous system signaling, immune cell activities and 
atherosclerosis.   There are a multitude of biological applications for ABPP in probing 
serine hydrolase activity.  The first application for ABPP involves comparing proteomes 
to determine and identify changes in enzyme activity levels. For instance, many serine 
hydrolases play an important role in cancer and analysis of an array of different human 
cancer cells have identified numerous serine hydrolases that are specifically elevated in 
aggressive cancer types (121-123).  For example, screens have identified increases in 
urokinase and tissue-type plasminogen activators, which are known to contribute to 
malignancy.  Additionally, comparisons have identified changes in serine hydrolases 
previously not linked to cancer such as MAG lipase and other uncharacterized serine 
hydrolases (121-123).  Interestingly, because ABPP monitors changed in activity and not 
gene expression, many of the aforementioned enzymes demonstrated changes in activity 
without having any changes in expression.   
 Changes in proteomes were monitored by fluorescence tagging of the serine 
hydrolases followed by SDS-PAGE fluorescence detection.  Unfortunately, there are 
limits to the resolution of these gels, which limits the number of serine hydrolases that 
can be monitored in these studies.  Because of this, new technologies coupling ABPP 
with LC-MS based platforms (termed multidimensional protein identification technology, 
ABPP-MudPIT) has allowed for deeper probing of the proteome (124).  This has led to 
	  37	  
the identification of hundreds of enzymes in proteomes and provides semi-quantitative 
information into the relative level of enzyme activities across varying proteomes.   
Additionally, ABPP has been used to identify new inhibitors for serine 
hydrolases, including enzymes with known and unknown functions. Inhibitor 
identification is achieved though a process termed competitive ABPP (Figure 14).   
I-14. Competitive ABPP 
 
 
Figure 14:  Competitive ABPP.  Fluorescence probes allow for identification of 
inhibitors for multiple serine hydrolases in the proteome.  
 
Competitive ABPP is possible because small molecules can compete against 
probes for binding in the active site of serine hydrolases, which causes a decrease in 
probe labeling.  These changes in probe binding can be resolved by either gel-based 
methods or by LC-MS proteomic approaches (125-128).  Because inhibitors are screened 
against entire proteomes, there is no need for purified protein for molecule screening.  
Additionally, since ABPP probes target a wide array of serine hydrolases, inhibitors can 
be developed for hydrolases with or without known substrates/function.  Finally, because 
inhibitors are screened against an entire proteome, off-target effects of inhibitors can be 
assessed in one experiment and inhibitors can be developed and modified to selectively 
inhibit one enzyme compared to others.   
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This competitive ABPP was critical in developing inhibitors for a multitude of 
serine hydrolases, including FAAH, MAGL and lysophospholipases (125, 127, 129-131).  
Inhibitors have been used to confirm the role of FAAH and MAGL in endocannabinoid 
metabolism.  Furthermore, development of lysophopholipase A1 and A2 (LYPLA1 and 
LYPLA2) inhibitors will allow for greater understanding of the function of these 
hydrolases beyond what little is know from present studies. 
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Dissertation Aims 
The major goal of the research described herein was to determine the identity of 
the serine hydrolase responsible for PG-G hydrolysis in human cancer cells. 
Understanding the roles prostaglandin glycerol esters play in physiological and 
pathophysiological states in vivo has been difficult due to the hydrolytic instability of 
these lipids. A significant effort was made to identify the serine hydrolase responsible for 
PG-G hydrolysis through numerous techniques; including protein purification, ABPP 
proteomics, and serine hydrolase inventory and PG-G hydrolase activity comparisons.  
Chapter II presents a newly developed MALDI-MS method for the detection of 
prostaglandins and prostaglandin glycerol esters.  This method facilitated speedier 
analysis of PG-Gs and PGs and allowed for high throughput methods for the 
development of COX-2 inhibitors.   Chapter III details the initial steps taken to identify 
the PG-G hydrolase present in human breast cancer cells, MDA-MB-231. Protein 
purification was initially employed in combination with ABPP-driven proteomics to 
isolated and identify proteins with hydrolytic activity.  Multiple serine hydrolases were 
identified and hydrolytic involvement was verified through cDNA overexpression in 
HEK293 cells and siRNA knockdown in MDA-MB-231 cells.  Unfortunately, the 
approach employed in Chapter III did not yield the identity of the hydrolase. This lead to 
a computational analysis of all serine hydrolases inventoried across various cancer cell 
lines.  This analysis led to the identification of lysophospholipase A2 (LYPLA2) as a 
serine hydrolase capable of metabolizing PG-Gs in human cancer cell lines.  Chapter IV 
discusses the work that led to the identification and verification, through siRNA 
knockdown in multiple cell lines and cDNA overexpression in HEK293, which helped 
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solidify LYPLA2 as the hydrolase of interest.  Additionally, recombinantly expressed 
LYPLA2 from E.coli was prepared. Kinetic analysis was performed on purified 
recombinant LYPLA2 against multiple substrates.  Also, specific inhibitors for both 
LYPLA1 and LYPLA2 were evaluated against LYPLA2.  Because LYPLA1 is closely 
related to LYPLA2, multiple studies were conducted to verify its involvement.  Studies 
included, siRNA knockdown of LYPLA1 in MDA-MB-231, cDNA overexpression in 
HEK-293 and recombinant overexpression in E.coli.  All studies verified that only 
LYPLA2 was responsible for PG-G hydrolysis.  Lastly, preliminary analysis of LYPLA2 
inhibition on lipid metabolism in cell culture was assessed in both RAW267.4 cells and 
1483 human head and neck squamous cell carcinoma. In sum, the findings presented 
provide the first steps into the identification, characterization and importance of LYPLA2 
in PG-G hydrolysis in both in vitro and in cells. Chapter V will contain a brief discussion 
of the implications of this research and any pressing questions that may exist. 
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Chapter II  
 
 
 
HIGH-THROUGHPUT QUANTIFICATION OF BIOACTIVE LIPIDS BY 
MALDI MASS SPECTROMETRY: APPLICATION TO PROSTAGLANDINS 
 
 
Introduction 
 
Quantification of individual or multiple analytes in biological systems is a critical 
element of enzymology, metabolomics and biomonitoring. The most commonly used 
methods employ chromatographic separation followed by mass spectrometric analysis. 
Quantification is achieved by stable isotope dilution methods using isotopically labeled 
internal standards. These methods are highly sensitive and specific, but they require 
considerable time for sample preparation and chromatographic separation and utilize 
serial rather than parallel sample handling. Matrix-assisted laser desorption/ionization 
mass spectrometry (132) (MALDI MS) is a powerful analytical technique capable of 
parallel processing of hundreds of samples without the need for prior separation (133).  
MALDI MS is extremely sensitive (low attomole – femtomole sensitivity) and fast, with 
analysis times in large part dependent on the frequency of the irradiating laser.  Solid-
state lasers with repetition rates of 1 kHz allow multiple samples to be analyzed in under 
one second (since typically many fewer than 1000 laser shots are needed) (134).  The fast 
analytical capability of MALDI MS is ideally suited for fast serial analysis of large 
numbers of samples. MALDI MS is widely used for characterization of protein samples 
but is not routinely employed in quantitative analyses. 
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We describe herein the development of a robust MALDI MS-based approach for 
the high-throughput analysis of an important class of bioactive lipids. Selective 
derivatization of ketone-containing prostaglandins (PGs) with positively charged 
hydrazines converted them to charged hydrazones that were readily quantified by 
MALDI MS. PGs are products of the cyclooxygenase (COX) pathway of arachidonic 
acid (AA) metabolism and PG-glycerol esters (PG-Gs) are products of oxygenation of the 
endocannabinoid, 2-arachidonoylglcyerol (2-AG) (Figure 1) (135).  
 
II-1. Conversion of AA and 2-AG to PGs and PG-Gs by COX-2 
 
Figure 1.  Conversion of AA and 2-AG to PGs and PG-Gs by COX-2. PGI2 and TxA2 
are unstable and rapidly hydrolyze to 6-keto-PGF1α and TxA2, respectively. 
 
As described, PGs and PG-Gs are potent lipid mediators that exert a broad range of 
biological responses through a series of membrane-bound G-protein-coupled receptors 
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(136). PGs have been implicated in diverse physiological and pathophysiological 
responses such as platelet aggregation, gastrointestinal integrity, wound healing, 
inflammation, hyperalgesia, and fever (137, 138). Many analytical methods have been 
described for their quantification based on mass spectrometry and they are widely applied 
in clinical and preclinical studies (139-142). All of the methods require extensive workup 
prior to analysis and/or time consuming HPLC separations followed by mass 
spectrometry. Because of the clinical importance of PG measurement, we developed a 
rapid high-throughput analytical method based on the derivatization of ketone-containing 
PGs followed by MALDI MS analysis. By using stable isotopically labeled internal 
standards, it was possible to develop quantitative mass spectrometric assays that 
displayed a large dynamic range. The assay was fully automated which enabled rapid 
liquid handling, high-throughput assay execution, and simultaneous deposition on a 384 
well MALDI target. Multiple reaction monitoring for a particular PG and its internal 
standard allowed parallel quantification of samples with high sensitivity, specificity, and 
speed. This method should be applicable to an extraordinarily wide-range of 
biomolecules and to applications ranging from high-throughput enzyme assays to 
targeted metabolomics.  
 
Materials and Methods 
Reagents:  AA was purchased from Nu-Chek Prep, Inc. (Elysian, MN, USA) 
Prostaglandin E2, prostaglandin D2, prostaglandin E2-d4, prostaglandin E2-1-glyceryl 
ester, 6-keto-prostaglandin F1α and (R)-flurbiprofen ((R)-(-)-2-fluoro-α-methyl-4-
biphenylacetic acid) were purchased from Cayman Chemicals (Ann Arbor, MI, USA). α-
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Cyano-4-hydroxy-cinnamic acid (CHCA), Girard’s reagent T, dimethyl sulfoxide 
(DMSO, Biotechnology performance certified), sulindac sulfide ((Z)-5-Fluoro-2-methyl-
1-[p-(methylthio)benzylidene]indene-3-acetic acid), indomethacin (1-(4-chlorobenzoyl)-
5-methoxy-2-methyl-3-indoleacetic acid) and (S)-flurbiprofen ((S)-(+)-2-fluoro-α-
methyl-4-biphenylacetic acid) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  All organic solvents were HPLC grade. Water and ethyl acetate were purchased 
from Fisher Scientific (Pittsburgh, PA, USA).  Acetonitrile was purchased from Acros 
(Morris Plains, NJ, USA).  Ethanol was purchased from Pharmco-AAPER (Shelbyville, 
KY, USA). RAW264.7 (RAW) cells were obtained from the American Type Culture 
Collection (ATCC) and were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with GlutaMax, high glucose, sodium pyruvate, and pyridoxine-
HCl purchased from Gibco (Grand Island, NY, USA). Heat-inactivated fetal bovine 
serum (hi-FBS) was purchased from Summit Biotechnologies (Fort Collins, CO, USA). 
Lipopolysaccharide (LPS) was purchased from Calbiochem (San Diego, CA, USA). 
Enzymes:  The expression and purification of recombinant murine COX-2 (mCOX-2) 
from SF-9 cells was performed as previously described (143).  
High-Throughput Screening Materials:  Labcyte (Sunnyvale, CA, USA) 384-well flat 
bottom polypropylene plates were used for the stock and reaction plates.  Tips for the 
384-tip head of the Agilent (Santa Clara, CA, USA) Bravo used in the study were 
purchased from Biotix (San Diego, CA, USA).   
Derivatization and Analysis of Prostaglandins:  Prostaglandin standards were dissolved 
in a solution of 1:1-ethanol:water to a final concentration of 20 µM.  Aliquots of this 
solution were mixed with an equivalent volume of Girard’s reagent T (10 mg/mL 
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solution in 20% acetic acid).  The mixture was allowed to react for 10 min at room 
temperature then added to an equivalent volume of a solution of 20 mg/mL CHCA in 
60% acetonitrile in water. A one µL aliquot was spotted on a MALDI plate (5 pmol 
analyte on-plate) and analyzed with a Bruker UltrafleXtreme TOF/TOF MS, Bruker 
Autoflex Speed TOF MS (Billerica, MA, USA) or on a Thermo LTQ-XL linear ion trap 
equipped with a MALDI source (San Jose, CA, USA) for MS/MS analysis of derivatized 
prostaglandins (PGE2 transition m/z 466.3→389.3, PGE2-d4 m/z 470.3→393.3).  
Mass Spectrometry Parameters:  All mass spectra were analyzed in positive ion mode.  
Both the Bruker UltrafleXtreme and Autoflex Speed TOF MS instruments are equipped 
with a Nd:YAG (solid state) laser at 355 nm utilizing SmartBeam™ modulation.  Both 
instruments were operated in reflector mode. The UltrafleXtreme was operated with the 
following settings: extraction voltage, 10 kV; delay time, 70 ns; mass range, 20-1000 
m/z. The Autoflex Speed was operated with the following settings:  extraction voltage, 19 
kV; delay time, 40 ns; mass range, 160-1000 m/z.  The LTQ-XL is equipped with a N2 
laser operating at 337 nm.  MS/MS experiments for individual analytes utilized a 
collision energy of 50, activation Q of 0.300, activation time of 50 ms and a product ion 
mass range of 150-600 m/z.   
COX-2 inhibitor assay:  The ability of COX-2 to oxygenate AA or 2-AG was quantified 
by monitoring conversion to PGE2 or PGE2-G. A solution of COX-2 protein (200 nM) 
was made in 100 mM Tris/ 500 µM phenol solution, with a 2x molar equivalent of 
hematin, and was preincubated for 5 min at room temperature.  A concentration range of 
inhibitors was added to aliquots of the enzyme solution and allowed to incubate at 37°C 
for 20 min.  AA was added to this solution (50 µM) and reaction allowed to proceed for 
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30 sec.  The solution was quenched with an equal volume of ethyl acetate (containing 
PGE2-d4 internal standard), the organic layer was collected and placed in a clean glass 
tube, then dried down under nitrogen.  Samples were reconstituted in 1:1-ethanol:water 
and derivatized with an equivalent volume of Girard’s reagent T (10 mg/mL solution in 
20% acetic acid) and analyzed by MALDI as described above.  All inhibitor 
concentrations for 50% enzyme activity (IC50) were calculated by nonlinear regression 
analysis using GraphPad Prism software. 
High-Throughput Analysis:  Modifications to the COX-2 inhibitor assay were made to 
adapt the standard assay to a high-throughput format.  Two 384-well stock plates were 
prepared with AA and inhibitors in DMSO.  Using a Labcyte Echo® Liquid Handling 
system, 50 nL of inhibitor was dispensed into a waiting 384-well reaction plate (DMSO 
was dispensed for no inhibitor control).  Each inhibitor concentration was tested in 
quadruplicate.  A solution of COX-2 (50 µL), containing 200 nM enzyme with 
appropriate cofactors as described above, was added to the reaction plate and allowed to 
incubate at 37°C for 20 min.  Using the Echo® system again, 750 nL of AA was added to 
another 384-well plate and placed on an Agilent BRAVO 384-well liquid handler.  To the 
waiting 750 nL of AA, 29.25 µL of the inhibitor/enzyme solution was added; samples 
were mixed using the BRAVO and allowed to react for 30 sec.  Thirty µL of the reaction 
solution was aspirated and dispensed into a pre-dispensed 30 µL of quench solution 
(Girard’s reagent T in 20% acetic acid in ethanol solution with PGE2-d4 internal 
standard).  These samples were allowed to react as described above.  Ten µL of the 
derivatized solutions was added to 10 µL of a 20 mg/mL solution of CHCA and 1 µL of 
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the final solution was spotted on a MALDI plate using the BRAVO.  All samples were 
analyzed using the Thermo LTQ ion trap mass spectrometer as described above (Chart 1). 
 
 
 
 
 
Chart 1.  Flow chart representing the protocol used for the high throughput analysis.  
Liquid handling with the Bravo is represented in black boxes (⎯) whereas liquid 
handling with the Echo is indicated in grey, dashed boxes (- - -). 
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Activated Macrophage Eicosanoid Analysis:  RAW cells were plated at 1.5 x 106 cells in 
a 30 mm dish in DMEM with 10% hi-FBS and 20 ng/mL of GM-CSF and allowed to 
incubate overnight.  After the overnight incubation, the medium was removed and fresh 
DMEM with 10% hi-FBS was added.  One set of cells was treated with only medium, the 
other set was treated with medium containing LPS (200 ng/mL) and IFNγ (20 U/mL) for 
6 hr followed by addition of AA (20 µM).  After 6 hr incubation, the medium was 
collected.  A 2:1-ethyl acetate:0.1% acetic acid solution was added to the collected 
medium.  Samples were vortexed, centrifuged (1000 x G for 5 min) and the organic layer 
was collected in clean glass tubes and dried down under nitrogen.  Samples were 
reconstituted in ethanol, derivatized as described above and analyzed using the Bruker 
Autoflex Speed TOF-MS.   
 
Results 
Method Development and Validation   
The ability to directly analyze prostaglandins using standard MALDI protocols and a 
number of different matrices in either positive or negative mode was assessed.  Figure 2a 
shows the mass spectrum for 3 PGs and a PG-G.  All spectra were dominated by peaks 
from the matrix (CHCA). It was determined that a charged moiety could be added to the 
analytes in order to improve detection by pre-ionizing the compounds.  Girard’s T 
reagent reacts with ketones to give hydrazone derivatives bearing charged moieties (144).  
Equation 1 displays the chemical reaction between PGE2 and Girard’s T reagent.   
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Equation II-1. Derivatization of PGE2 by Girard’s T 
 
Equation 1: Derivatization of PGE2 by Girard’s T 
 
Figure 2b represents the mass spectra obtained from the same prostaglandins 
derivatized with the Girard’s T reagent.   The mass spectra are dominated by the expected 
masses of the derivatized prostaglandins (PGE2 m/z = 466.3, PGD2 m/z = 466.3, PGE2-G 
m/z = 540.3 and 6-keto-PGF1α m/z = 484.3) and have a much higher signal to noise then 
their underivatized counterparts (Fig. 2a).  Ions were observed at m/z = 448 in both PGE2 
and PGD2 spectra corresponding to dehydration products likely formed by the acidic 
Girard’s reagent T. A matrix ion was observed at m/z = 455. 
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II-2. MALDI mass spectra of PGE2, PGD2, PGE2-G, and 6-keto-PGF1α before and after derivatization with Girard’s T 
reagent 
 
 
Figure 2.  MALDI mass spectra of PGE2, PGD2, PGE2-G, and 6-keto-PGF1α before 
(A) and after (B) derivatization with Girard’s T reagent.  All mass spectra were 
obtained with CHCA matrix in the positive ion mode.  The spectra in (A) are dominated 
by a protonated CHCA-dimer signal at m/z 379.1.  The area surrounding this signal was 
increased 10x for all four spectra.  The expected [M+H]+ ions are indicated with asterisks 
in (A) at m/z 353.2, 353.2, 427.3, and 371.2 for PGE2, PGD2, PGE2-G, and 6-keto-PGF1α, 
respectively. The expected Girard’s T products are shown in (B) at m/z 466.3, 466.3, 
540.4, and 484.3, respectively. 
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To assess linearity, the lower limit of detection, and the potential for signal 
interference, an 8-point concentration curve of PGE2 and PGE2 mixed with PGE2-G 
(PGE2-d4 was added as internal standard) was constructed in triplicate from 15 fmol on-
plate to 2000 fmol on-plate. Quantification of PGE2 and PGE2-G was based on the MS2 
transitions: m/z 466.3→389.3 for PGE2 and m/z 540.3→463.3 for PGE2-G (Supplemental 
Figure 1).  Figure 4 displays the concentration-response curves for PGE2 alone and PGE2 
in solution with PGE2-G.   
 
II-3. Representation of standard curves for both PGE2 in solution alone and PGE2 in solution with PGE2-G.   
 
Figure 3.  Representation of standard curves for both PGE2 in solution alone (!) 
and PGE2 in solution with PGE2-G (").  The equations representing the depicted 
regression lines for PGE2 alone was y = 4e-5x - 0.0008 and PGE2 mixed with PGE2-G 
was y = 4e-5x - 0.005 .  The regression lines for either analyte did not differ significantly 
from unity (r2=0.99).  
 
The regression of the lines for PGE2 alone and PGE2 mixed with PGE2-G are 
similar and neither slope differs significantly from unity (r2=0.99). No signal interference 
was observed between the two curves demonstrating that neither prostaglandin affected 
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the analysis of the other on-plate. This signal response and sensitivity is comparable to 
that obtained from LC-MS/MS (data not shown). 
 
COX-2 Inhibitor Assay: 14C-TLC or Oxygen Consumption vs. MALDI MS/MS   
Analysis of COX activity and inhibition is routinely assessed by monitoring AA 
metabolism, prostaglandin formation or oxygen consumption utilizing either a 14C-thin 
layer chromatography (TLC) method or a polarographic electrode to monitor oxygen 
consumption (145, 146).  Though both methods give accurate assessments for the 
analysis of COX activity, each has disadvantages. MALDI MS/MS analysis has the 
ability to analyze COX activity by using non-radioactively labeled material and has much 
faster analysis time compared to either 14C-TLC or oxygen electrode-based analysis.  In 
addition, the large dynamic range of the MALDI detection method enables the use of a 
wide range of enzyme, substrate, and inhibitor concentrations.   
MALDI MS analysis was used to determine the IC50 value for inhibition of COX-
2 by the known non-selective inhibitor, indomethacin. The results were compared with 
the IC50 values obtained from either 14C-TLC or oxygen electrode assays.  Figure 5 
displays the IC50 curves obtained from MALDI MS analysis for indomethacin.  The IC50 
value for indomethacin obtained from the 14C-TLC method was 210 nM (147) which is 
comparable to the IC50 of 200 nM obtained from MALDI MS/MS analysis. The IC50 
value obtained using an oxygen consumption assay was 900 nM (148) (Figure 5).   
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II-4. IC50 values for COX-2 inhibitor, indomethacin, determined by MALDI MS/MS; validation of Girard’s 
reagent T as quench 
 
Figure 4.  IC50 values for COX-2 inhibitor, indomethacin, determined by MALDI 
MS/MS; validation of Girard’s reagent T as quench.  The IC50 value of indomethacin 
inhibition of COX-2 was determined using either ethyl acetate as a quench (!) followed 
by Girard’s T reagent or direct addition of Girard’s reagent T in 20% acetic acid in 
ethanol as a quench (  ),with similar IC50 values of 200 nM and 180 nM, 
respectively. 
 
 
The oxygen electrode used for oxygen uptake method is relatively insensitive, which 
requires higher enzymes and substrate concentrations, which may account for the higher 
IC50 determined by this method. It is clear that by using MALDI MS analysis it is 
possible to obtain comparable results to either the 14C-TLC or the oxygen uptake methods 
in dramatically shortened times.  
 
COX-2 Inhibitor Assay - High Throughput Screening (HTS) Method Development   
The rapidity of analysis by MALDI MS/MS makes it attractive to combine it with 
high-throughput liquid handling.  We proceeded to develop a high-throughput assay for 
the analysis of inhibitors against either isoform of COX by analysis of PGE2 formation.  
This was accomplished through a combination of ultra-low volume acoustic liquid 
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handling using a Labcyte Echo to produce the test compound plates and a Bravo liquid 
handler controlled by VWorks (Agilent, Santa Clara, CA, USA) using a 384-tip pipetting 
head. The highly accurate and rapid pipetting and mixing with the Bravo together with 
the precise timing of assay steps afforded by using VWorks allowed facile, rapid, and 
reproducible execution of 384 parallel enzyme reactions, derivatizations and spotting 
operations. We found that reactions could be quenched with Girard’s T reagent, which 
eliminated the liquid-liquid extraction and sample evaporation steps.  Figure 5 presents a 
comparison of the concentration-dependent inhibition curves obtained with indomethacin 
using ethyl acetate quench or direct addition of Girard’s T as a quench.  Both methods 
gave comparable results so it was determined that a high-throughput assay could be 
developed without the need for a liquid-liquid extraction.      
Once the method was developed, we validated the assay by assessing the IC50 
values obtained from four known COX-2 inhibitors.  Figure 6A displays the results 
obtained from the analysis of the inhibition of COX-2 to metabolize AA by indomethacin 
and sulindac sulfide. The measured IC50 values (indomethacin IC50 = 65 nM, sulindac 
sulfide IC50 = 290 nM) are comparable to previously reported values, although there is 
some difference between the value of 65 nM for indomethacin and the value of 200 nM 
measured with manual pipetting and sample handling. In addition to potent COX-2 
inhibitors, the ability to distinguish an inhibitor from a non-inhibitor was determined by 
assessing COX-2 inhibition by stereoisomers flurbiprofen.  Figure 6B displays the results 
obtained from the analysis of inhibition of COX-2 to metabolize AA by (S)-flurbiporfen 
and (R)-flurbiporfen.  The measured IC50 values ((S)-flurbiprofen, IC50 = 120 nM; and 
(R)-flurbiprofen, no inhibition) were comparable to previously reported values (147-149).  
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The HTS method is capable of assessing COX-2 inhibition of a number of different 
known COX-2 inhibitors as well as distinguish between compounds that do and do not 
inhibit COX-2.   
 
II-5. IC50 values determined for COX-2 inhibitors using the high throughput assay 
 
Figure 5.  IC50 values determined for COX-2 inhibitors using the high throughput 
assay.  (A) COX-2 inhibitors indomethacin (#) and sulindac sulfide($) were assessed 
against COX-2 metabolism of AA.  IC50 values determined were 65 nM and 290 nM, 
respectively.  (B) Sterioisomers R-flurbiprofen  (!) and S- flurbiprofen (!) were 
assessed against COX-2 metabolism of AA.  IC50 values determined were no inhibition 
and 120 nM, respectively. 
 
MALDI TOF analysis of Activated Macrophages  
Analysis of AA metabolism in cultured cells has been performed mainly by LC-
MS analysis (150).  These methods have demonstrated the formation of a number of 
different prostaglandins, including PGE2/D2 and 15-keto-13,14-dihydro-PGE2.   Previous 
work also has shown that RAW cells treated with LPS/INF-γ have increased levels of 
COX-2, and addition of AA leads to increased production of PGD2 (151).  To assess 
whether this derivatization method could be applied to the analysis of cellular metabolism 
of AA, RAW cells were treated as described in Materials and Methods.  Medium from 
56	  
these cells was extracted and analyzed on a MALDI TOF MS.  Figure 7 is a comparison 
between blank CHCA, Girard’s T reagent only, untreated RAW cells and RAW cells 
treated with AA. When cells were treated with AA, increased levels of PGD2 (m/z = 
466.3) were detected which were similar to previous studies of LPS/INF-γ treated RAW 
cells (151). As seen from previous work in our lab, activation of RAW cells with LPS 
treatment stimulated the production of PGD2 compared to untreated samples (151).  The 
utilization of the MALDI MS method allows us to quantify prostaglandins at levels 
similar to those quantified by LC-MS/MS analysis.  
II-6.  MALDI MS of media extracted from LPS-activated RAW cells 
 
Figure 7.  MALDI MS of media extracted from LPS-activated RAW cells.  Cells 
dosed with AA (AA) showed increases in the formation of PGD2 (m/z = 466.3) 
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Discussion 
 We have successfully analyzed ketone-containing prostaglandins after 
derivatization with Girard’s T reagent by MALDI MS.  We assessed the suitability of 
using MALDI to detect the production of prostaglandins in an endpoint assay for COX-2 
inhibition.  Initially MALDI MS was used as the analytical tool to detect derivatized 
prostaglandins, however we wanted to assess its suitability for high-throughput analyses.   
We determined that Girard’s T reagent solution could be added as the quench for the 
assay, making it suitable for the automated process. We utilized state-of-the art liquid 
handling robotics to assay the biological activity of COX-2 in the presence of several 
inhibitors.  The entire process was automated from substrate aliquoting, enzyme addition, 
reaction quenching, matrix mixing, and application to a 384-well MALDI plate and 
automated MS analysis.  Three hundred eighty-four independent biochemical assays can 
be completed from initial incubation to final analysis in approximately 6 hr.  This is a 
drastic improvement in time and number of samples analyzed compared to other 
analytical techniques.  
 Additionally, we wanted to assess the capability of this newly developed MALDI 
method to analyze more complex cellular samples.  We showed that we are able to obtain 
comparable results to LC-MS, again in a fraction of the time.  This was demonstrated 
from the analysis of extracted media from activated macrophages where we found 
increased production of PG’s in AA-treated RAW cells compared to untreated cells.  
Individual data points were acquired in less than a second using no more than 1 uL of 
samples compared to ~15 min for a complete LC separation (142). 
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 In the quarter of a century since MALDI was first described, it has been one of 
the prime technologies that has revolutionized the analysis of biological samples, 
especially the study of peptides and proteins.  As the speed and resolution of mass 
spectrometry technology has advanced, it now holds great potential for high-throughput 
analysis.  This report has demonstrated the efficacy of MALDI MS for the high-
throughput, sensitive, and quantitative analysis of prostaglandins in complex samples 
including whole cells.  This technology has wide application in many areas of biological 
and chemical analysis.   
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Supplemental Information 
 
 
 
Supplemental Figure 1.  MALDI MS/MS for PGE2 and PGE2-G.  Derivatized PGE2 
and PGE2-G ions were subjected to collisionally activated dissociation in a linear ion trap 
in order to determine the optimal transitions for SRM analysis.  The fragments chosen for 
MS2 of PGE2 and PGE2-G were m/z = 389.3 and 463.3 (indicated by "), respectively.  
These signals were chosen because they were unique and gave the largest intensity which 
allowed for accurate quantification and good sensitivity.  Full scan and MS2 spectra for 
PGE2-d4 were also acquired (data not shown) and showed similar intensity and 
fragmentation as PGE2. 
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Chapter III  
 
 
 
IDENTIFICATION OF A PROSTAGLANDIN GLYCEROL ESTER 
HYDROLASE IN MDA-MB-231 CANCER CELLS BY PROTEIN 
PURIFICATION 
 
Introduction 
A growing field of interest in lipid metabolism has focused on the role of a group 
of oxidation products formed by cyclooxygenase 2.  These metabolites are formed from 
the oxidation of endocannabinoids, 2-arachidonoylglycerol  (2-AG) and N-
arachidonylethanolamine (AEA), to form the prostaglandin derivatives, namely 
prostaglandin glycerol esters (PG-Gs) and ethanolamine (PG-EAs). Investigation into the 
physiological effects of these lipids began with insights into the effects the synthetic 
PGF2α-EA analog, bimatoprost, elicited during treatment of ocular hypertension (88). 
Bimatoprost and PGF2α-EA exerted the same effect on intraocular pressure as PGF2α, but 
through action on the heterodimer of the FP receptor, comprised of a wild type FP 
receptor and a splice variant of the FP receptor with a shortened C-terminus (88). PG-Gs 
also exert an array of physiological responses. PGE2-G caused an increase in Ca2+ 
mobilization, which was independent of any known prostaglandin receptor activation and 
dependent on the synthesis of IP3 and diacylglycerol. Ca2+ mobilization and 
diacylglycerol synthesis led to the activation of PKC and an increase in ERK 
phosphorylation. (82, 86). Additionally, PGE2-G can induce hyperalgesia and modulate 
NF-κB activation (85), as well as induce pro-inflammatory and neurotoxic effects (93).  
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Interestingly, PGD2-G and its metabolite 15-deoxy-Δ12,14 prostaglandin J2-glycerol ester 
exert anti-inflammatory effects (94, 95). 
Though PG-Gs can elicit a wide array of biological responses in an in vitro 
setting, understanding in vivo effects of these lipid metabolites has been difficult due to 
hydrolytic instability.  Vila et. al. showed that PGE2-G is rapidly hydrolyzed in rat 
plasma post intravenous administration, with no detectable levels after 5 minutes. They 
attributed this instability to the presence of plasma esterases that hydrolyze PG-Gs. 
Initially, endocannabinoid hydrolyzing enzymes, fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL), were examined as potential PG-G hydrolyzing 
enzymes (97).  However, kinetic analysis showed that PG-Gs were very poor substrates 
for hydrolysis by these enzymes. Furthermore, use of the organophosphate pesticides lead 
to the identification of carboxylesterase 1 (CES1) and palmitoyl protein thioesterase 1 
(PPT1) as esterases capable of hydrolyzing both 2-AG and PG-Gs (98). Beyond CES1 
and PPT1, there is evidence to suggest the existence of other enzymes responsible for 
PG-G hydrolysis.  
Utilizing protein purification techniques coupled with mass spectrometric 
analysis, we ventured to identify the enzyme responsible for PG-G hydrolysis in MDA-
MB-231 cancer cells.  These cancer cells were chosen for a multitude of reasons; they do 
not express CES1, PPT1 or MAGL, they are easy to maintain, and they exhibit 
significant PGE2-G hydrolytic activity.  Multiple purification techniques led to the 
identification of three enzymes by proteomics as potential PG-G hydrolase targets; 
namely 6-phosphoglucolactonase (PGLS), dimethylarginine dimethylaminohydrolase 2 
(DDAH2), and platelet activating factor acetylhydrolase 1β3 subunit  (PAFAH1β3). 
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Unfortunately, further validation did not support the involvement of these proteins in 
hydrolysis. Here we present the purification scheme utilized and the results obtained from 
purification, proteomics and validation of identified enzymes through gene silencing and 
protein overexpression.  
 
Materials and Methods 
Cells and Reagents. Prostaglandin glycerol esters (PGE2-1 glycerol ester), deuterated 
prostaglandins and prostaglandin glycerol esters (PGE2-d4 and PGE2-G-d5) were 
purchased from Cayman Chemicals (Ann Arbor, MI). LC-MS solvents were purchased 
from Fisher Scientific (Chicago, Il).  DharmaFECT 1 was purchased from Thermo 
Scientific (Pittsburgh, PA). Human breast cancer adenocarcinoma cell lines; MDA-MB-
231, and human embryonic kidney cells; HEK293 were from American Type Culture 
Collection (ATCC, Manassas, VA).  Recombinant cDNA and Turbofect were purchased 
from OriGene Technologies (Rockville, MD). FBS was purchased from Atlas Biologicals 
(Fort Collins, CO).  
Culture Conditions. MDA-MB-231 and HEK293 were maintained as adherent cultures in 
RPMI (Gibco) media supplemented with 10% (v/v) fetal bovine serum (FBS, Atlas) at 
37°C and 5% CO2. 
Serine Hydrolase Inhibition. The general serine hydrolase probe, methoxy 
fluorophosphonate coupled to tetramethylrhodamine (FP-TAMRA, purchased from 
Thermo), was used to determine the involvement of serine hydrolases in the metabolism 
of prostaglandin glycerol esters. FP-TAMRA (100 nM) or DMSO was added to 100 uL 
of MDA-MB-231 cytosol and allowed to incubate for 30 mins at 37°C. Samples were 
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treated as mentioned in Prostaglandin Glycerol Ester Hydrolase Assay, with the 
following changes.  Samples were allowed to incubate from 0 to 60 mins to obtain a full 
hydrolysis time course.   
Protein Purification of PGE2-G Hydrolase(s): All steps were carried out at 4°C.  All 
chromatographic steps were carried out using an AKTA FPLC protein purification 
system.  All buffers were made the day prior to use and cooled to 4°C.  All columns were 
from GE Healthcare.   
(A) Cytosolic Preparation. Ten grams of MDA-MB-231 cells (GenScript) was taken 
and resuspended in 25 mM Tris (pH 7.4) supplemented with 0.5 mM of EDTA and DTT, 
no protease inhibitors could be used because many of these inhibitors inhibit PG-G 
hydrolysis.  Cells were lysed by sonication (Virsonic Cell Disrupter model 16-850, 10 x 
10 sec pulses at relative output of 0.5, on ice). Cell lysates were taken and cytosolic 
fractions were isolated by centrifugation (100,000 x g for 1 h).   
(B) Strong Cation Exchange. Cytosol was passed over a HiTrap SP FF cation 
exchange column (5 mL column), preequilibrated with 200 mM phosphate buffer (pH 6) 
with 0.1 mM DTT and EDTA, flow rate 1mL/min; all flowthrough was collected.  
Utilizing a strong cation exchange column allowed for the removal of unwanted 
proteases.    
(C) Strong Anion Exchange - High Q.  Flow through was dialyzed overnight (2000 
molecular weight cut off (MWCO) dialysis cassette, Thermo) against 20 mM Tris (pH 
7.4) with 0.2 mM EDTA and 0.1 mM DTT (Q Buffer A).  Sample was loaded onto a 
HiTrap Q FF anion exchange column (20 mL) preequilibrated with Q Buffer A.  Column 
was washed with 4 column volumes of Q Buffer A and eluted with a linear gradient of 0-
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100% elution buffer (20mM Tris (pH 7.4) with 500 mM NaCl, 0.1 mM EDTA and DTT, 
Q Buffer B). Fractions were tested for hydrolytic activity using the method mentioned in 
Prostaglandin Glycerol Ester Hydrolysis section below.   
(D) Size Exclusion. Active fractions were pooled and concentrated to 3 mL using a 
3000 MW cutoff centrifugal filter unit (Millipore). Sample was applied to a 120 mL size 
exclusion column packed with Sephacryl S-200 resin preequilibrated with 20 mM bis-
Tris HCl (pH 7.1) supplemented with 0.1mM EDTA and DTT and fractions were 
collected and tested for hydrolytic activity.  
(E) Mono-P. Active fractions were pooled and applied to a 4 mL MonoP column 
prequilibrated with 20mM Bis-Tris HCl (pH 7.1) supplemented with 0.1 mM EDTA and 
DTT.  Proteins were eluted using a linear gradient from 0-100% of Polybuffer 74 (GE 
Healthcare) diluted in ultrapure water and pH adjusted to pH 4 using iminodiacetic acid. 
Fractions were collected and tested for hydrolytic activity. 
(F) Mono-Q. Active fractions were pooled and dialyzed overnight against Q Buffer 
A.  Samples were applied to a Mono-Q anion exchange column preequilibrated with Q 
Buffer A.  Proteins were eluted using a linear gradient from 0-100% Q Buffer B.  Eluted 
protein fractions were collected and tested for hydrolytic activity.  Active fractions were 
pooled and taken for ABPP and proteomic analysis.   
(G) Polyacrylamide Gel Electrophoresis. SDS-polyacrylamide gels (4-20% gradient 
gel) were run under reducing conditions and stained with colloidal Coomassie blue.    
Competitive Activity Based Protein Profiling (ABPP). Figure 1 represents the scheme for 
competitive ABPP.  Generally, samples from the final step of purification were taken and 
competitive activity based protein profiling was conducted.   
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III-1. Scheme of Competitive ABPP 
 
Figure 1: Scheme of Competitive ABPP 
 
Aliquots were treated with either DMSO or 20 mM of PGE2-G and allowed to 
interact for 5 minutes at room temperature. This ensures PGE2-G binding into the 
catalytic pocket of the serine hydrolase of interest. 100 µM of fluorophosphonate (FP) 
bound to a tetramethylrhodamine (TAMRA), was added to each sample and allowed to 
incubate for an additional 30 mins.  FP-TAMRA binds to the catalytically active serine in 
serine hydrolases.  Adding an equal volume of Laemmli blue with SDS and boiling 
quenched binding.  Denatured samples were run on a SDS-PAGE gel as mentioned above 
and FP-TAMRA bound proteins were visualized using a BioRad imager.  Samples that 
showed decreased FP-TAMRA tagging in the presence of excess PGE2-G were excised 
for tryptic digestion and proteomics. 
Proteomic Preparation and Analysis. Protein fractions were resolved by 4-20% SDS-
PAGE, the gel was stained with colloidal Coomassie, and bands of interest were excised 
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from the gel and cut into 1mm3 pieces. The gel pieces were treated with 45 mM DTT for 
45 minutes, and available Cys residues were carbamidomethylated with 100 mM 
iodoacetamide for 45 min. After destaining the gel pieces with 50% MeCN in 25 mM 
ammonium bicarbonate, proteins were digested with trypsin (10ng/uL) in 25 mM 
ammonium bicarbonate overnight at 37°C. Peptides were extracted by gel dehydration 
(60% MeCN, 0.1% TFA), the extract was dried by speed vac centrifugation, and peptides 
were reconstituted in 0.1% formic acid. The peptide extracts were then loaded onto a 
capillary reverse phase analytical column (360 µm O.D. x 100 µm I.D.) using an Eksigent 
NanoLC Ultra HPLC and autosampler. The analytical column was packed with 20 cm of 
C18 reverse phase material (Jupiter, 3 µm beads, 300Å, Phenomenox), directly into a 
laser-pulled emitter tip.  Peptides were gradient-eluted at a flow rate of 500 nL/min, and 
the mobile phase solvents consisted of 0.1% formic acid, 99.9% water (solvent A) and 
0.1% formic acid, 99.9% acetonitrile (solvent B).  A 90-minute gradient was performed, 
consisting of the following:  0-10 min, 2% B; 10-50 min, 2-40% B; 50-60 min, 40-90% 
B; 60-65 min, 95% B; 65-70 min 95-2% B; 70-90 min, 2% B.  Eluted peptides were mass 
analyzed on an LTQ Orbitrap XL mass spectrometer (Thermo Scientific), equipped with 
a nanoelectrospray ionization source. The instrument was operated using a data-
dependent method with dynamic exclusion enabled. Full scan (m/z 400-2000) spectra 
were acquired with the Orbitrap (resolution 60,000), and the top 5 most abundant ions in 
each MS scan were selected for fragmentation via collision-induced dissociation (CID) in 
the LTQ. An isolation width of 2 m/z, activation time of 30 ms, and 35% normalized 
collision energy were used to generate MS2 spectra. Dynamic exclusion settings allowed 
for a repeat count of 1 within a repeat duration of 5 sec, and the exclusion duration time 
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was set to 15 sec.  For identification of proteins, tandem mass spectra were searched with 
Sequest (Thermo Fisher Scientific) against a Homo sapiens subset database created from 
the UniprotKB protein database (www.uniprot.org).  Variable modifications of +57.0214 
on Cys (carbamidomethylation), and +15.9949 on Met (oxidation) were included for 
database searching. Search results were assembled using Scaffold 3.0 (Proteome 
Software), peptide and protein identifications were filtered to 95% and 99% probability, 
respectively, and proteins reported were required to have two or more peptides identified. 
Prostaglandin Glycerol Ester Hydrolase Assay. Hydrolytic activity was determined by 
addition of 10 nmol of PGE2-G to 100 µL of cytosol at 37°C.  Reactions were quenched 
after 2 h by addition of 1mL of ethyl acetate containing deuterated internal standard 
(PGE2-d4).  Quenched samples were placed on ice for 15 minutes before the organic layer 
was removed, evaporated to near dryness under nitrogen and reconstituted with 50% 
methanol. Samples were analyzed by LC-MS/MS analysis for the hydrolytic products 
PGE2 and samples were quantified against the internal standard.   
LC-MS/MS Analytical Procedures. Analysis of prostanoids was accomplished by reverse 
phase chromatography followed by mass spectrometric detection by selected reaction 
monitoring (SRM).  The LC system used was a Shimadzu LC-20 and the mass 
spectrometer used was an Applied Biosystems 3200 QTrap.  Resolution of PGs was done 
by gradient elution on a Phenomenex Luna C18 column (50 mm x 2.0 mm, 3 µm particle 
size).  Solvent A was HPLC grade water with 0.1% formic acid and solvent B was 
acetonitrile (ACN) with 0.1% formic acid.  Samples were injected onto the column with a 
starting condition of 80% solvent A and 20% solvent B at a flow rate of 0.5 mL/min.  A 
linear gradient of increasing solvent B to 98% was run over 2 minutes and then held for 
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1.5 minutes.  
Protein expression in HEK293 Cells. HEK293 cells were plated at a density of 3x105 
cells per well in a 6-well plate in RPMI medium supplemented with 10% FBS and were 
incubated for 24 h at 37°C.  cDNA transfections were performed according to 
manufacturer’s recommendations.  Briefly, Turbofect and cDNA (1.5 µg) were added to 
serum free OPTIMEM medium and allowed to incubate at room temperature for 30 min.  
cDNA solution was added to each well drop wise and cells were incubated at 37°C for 
additional 48 h before harvesting.    
siRNA Knockdown of Identified Proteins (PGLS and PAFAH1β3). siRNAs for PGLS and 
PAFAH1β3 were purchased from Life Technologies.  MDA-MB-231 cells were plated at 
1.0 x 106 cells per 100mm2 and allowed to incubate for 24 h to give 40-60% confluence.  
siRNA was introduced into the cells by complex formation with either siRNA and 
DharmaFECT 1 according to manufacturer’s recommendations.  Briefly, 
siRNA/DharmaFECT complexes were formed for 20 min in serum free OPTIMEM1 
(Gibco).  RPMI medium from each plate was removed and replaced with 5 mL of serum-
free OPTIMEM1 medium followed by addition of 1 mL of transfection solution.  Cells 
were cultured for 24 h at 37°C.  Medium was subsequently replaced with RPMI 
containing 10% FBS and incubated at 37°C for an additional 48 h before harvesting. 
Western Blot Analysis. Protein expression was determined in all cell lysates by western 
blot analysis.  Cell lysates were all separated by sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE).  Following SDS-PAGE separation, proteins 
were transferred onto a nitrocellulose membrane and probed with either anti PGLS, anti-
DDAH2 or anti-PAFAH1β3 (1:500 v/v) and anti-GAPDH (1:1000, v/v) overnight 
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followed by incubation with IR visible secondary antibodies (1:5000, v/v).  Blots were 
visualized using the Odyssey IR Imager. 
 
Results 
Characterization of PGE2-G Hydrolysis in MDA-MB-231 Cancer Cells 
MDA-MB-231 breast cancer cells were initially tested for hydrolytic activity by 
quantitatively monitoring the formation of PGE2 by LC-MS/MS.  Cytosolic fractions 
demonstrated PGE2-G hydrolase activity that was linear with time and comparison to 
membrane fractions from the same cells revealed that virtually all of the activity was 
cytosolic (Figure 2). Importantly, serine esterases have been proposed as the hydrolases 
responsible for PG-G hydrolysis in rat plasma. Thus, we explored whether a member of 
the serine hydrolase family was responsible for PGE2-G hydrolysis. MDA-MB-231 
cytosol was preincubated with an irreversible serine hydrolase inhibitor, methoxy 
fluorophosphonate, and assessed for hydrolytic activity following incubation. As shown 
in Figure 2, fluorophosphonate treatment abolished hydrolysis of PGE2-G. This supports 
the hypothesis that a serine hydrolase is responsible for PGE2-G in MDA-MB-231 cells. 
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III-2. PGE2-G hydrolase activities in MDA-MB-231 
 
Figure 2: PGE2-G hydrolase activities in MDA-MB-231. (A) Cellular fractionation of 
MDA-MB-231 cells displayed PGE2-G hydrolase activity in the cytosolic fraction. 
Membrane fractions demonstrated no activity. (B) MDA-MB-231 cells displayed PGE2-
G hydrolase activity that was abolished by pretreatment with an irreversible 
fluorophosphonate inhibitor, FP-TAMRA. 
 
 
Purification of unknown PG-G Serine Hydrolase 
Cytosol was isolated from a 10 g pellet of MDA-MB-231 and applied to a strong 
cation exchange column to remove unwanted proteases.  Protease inhibitors could not be 
used because many of these inhibitors are general serine hydrolase inhibitors, which 
caused complete inhibition of PGE2-G hydrolysis in cytosol (data not shown).  The 
dialyzed flow-through fraction was applied to a High-Q anion exchange column and 
eluted with a NaCl gradient.  No hydrolytic activity was present in the void volume.  A 
salt gradient was run and PGE2-G hydrolase activity was eluted from the column at 
approximately 200 mM salt concentration.  The active fractions were combined, 
concentrated and loaded onto a size exclusion column.  The hydrolytic activity eluted 
from the size exclusion column at masses corresponding to a range of 75-25 kDa (Figure 
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3).  The active fractions were pooled and applied to a chromatofocusing (Mono-P) 
column for further separation by pH. Interestingly, only 2 hydrolytically active fractions 
eluted from the chromatofocusing column at a pH of approximately 6 (Figure 3). 
Unfortunately, the levels of PGE2-G hydrolysis from fractions isolated from the size 
exclusion column were significantly higher (top fraction produced ~10,000 ng/mL of 
PGE2) compared to PGE2-G hydrolysis from the Mono-P column (top fraction produced 
~2500 ng/mL of PGE2). This represents a decrease of 75% of the amount of PGE2 
produced in the most active fraction. Potentially, the enzyme was unstable through the 
Mono-P column due to drastic changes in pH.  Many proteins have been reported that are 
unstable at lower pH.  
Active fractions isolated from Mono-P column were combined, dialyzed and 
further purified using a Mono-Q anion exchange column to produce highly pure samples 
(Figure 3).  Mono-Q columns are commonly used to refine the final step in purification 
because of the homogenous size of the beads in the packing material. The levels of PGE2-
G hydrolysis are not significantly changed through this column (top fraction produced 
2400 ng/mL of PGE2), which is comparable to the Mono-P column, suggesting that we 
did not lose much activity through this column.
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III-3. Elution and activity profiles for PG-G hydrolase purification 
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Overall, hydrolytic activity was purified 138-fold compared to cytosolic extracts (Table 
1). As stated above, there appears to be no significant increase in purity (~2-fold 
increase) between the size exclusion column and the Mono-Q column, implying the 
Mono-P column is either not contributing to purification, or may be detrimental to the 
purification due to significant decreases in PGE2-G hydrolysis from the size exclusion 
column to the Mono-P column.  Unfortunately specific activity was difficult to determine 
because the Polybuffer 74 required for the Mono-P chromatography interfered with 
protein determination, though it did not interfere with activity determinations.   
 
Table1: Purification Table of PG-G Hydrolase from MDA-MB-231 
III-1. Purification Table of PG-G Hydrolase from MDA-MB-231 
  
MonoP not determined (N/D) because Polybuffer 74 interfered with BCA protein determination 
 
The yield is comparable to other purifications of serine hydrolases.  However, the fold 
purification was significantly lower then those observed from other serine hydrolase 
purifications, which could also be associated with the loss in PGE2-G hydrolysis between 
size exclusion chromatographic separation and Mono P chromatographic separation.   
To determine the extent of purification, all steps from the purification were run on 
a 4-20% SDS-PAGE gel and stained by colloidal Coomassie blue.  Figure 4 shows the 
Samples 
Total 
Protein 
(mg) 
Total 
Activity 
(units) 
Specific 
Activity 
(Units/mg) 
Fold 
Purification % Yield 
Cell Lysate 215 1248430 5804 1 100 
Cytosol 219 1225410 5590 1 98 
Strong Cation  FT 87 713050 8242 1 57 
HiTRAP Q Column 6 450814 78850 14 36 
Size Exclusion  1 242648 394478 68 19 
Mono-P N/D 17179 N/D N/D N/D 
Mono-Q 1> 26280 1600812 138 2 
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protein bands present in all the steps.  The purification resulted in a significant decrease 
in the number of proteins in the samples, with intense bands present at 25kDa and 50kDa, 
and 4-5 minor protein bands throughout.  Competitive ABPP was used to determine 
which proteins from the Mono-Q were capable of binding PGE2-G.   
 
III-4. SDS-PAGE gel with Coomassie blue staining for each step in purification 
 
Figure 4:  SDS-PAGE gel with Coomassie blue staining for each step in purification.  
The amount of protein present in the cell lysate and cytosol is significantly purified down 
to a few bands in the Mono-Q fractions.  The most intense band present in the Mono-Q 
corresponds to a protein at 25kDa 
 
Characterization of PG-G binding by Competitive ABPP 
Competitive activity-based protein profiling was conducted to determine proteins 
corresponding to PGE2-G binding.  The assumption was that any serine hydrolase that 
can bind PGE2-G in the active site may be responsible for hydrolysis. Samples from the 
Mono-Q column were treated with excess PGE2-G or DMSO followed by FP-TAMRA 
tagging.  Competitive ABPP yielded a protein with an apparent molecular weight of 
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25kDa that resulted in inhibition of FP-tagging in the presence of PGE2-G (Figure 5).   
The ability of PGE2-G to block FP binding demonstrated a serine hydrolase capable of 
binding PG-Gs at the active site serine. This protein band also correlated to the darkest 
band by colloidal Coomassie blue staining (Figure 5) and was excised for in-gel tryptic 
digestion and protein identification.   
III-5. PGE2-G Competitive ABPP 
 
Figure 5:  PGE2-G Competitive ABPP.  Excess PGE2-G in purified fractions inhibited 
the labeling by FP-TAMRA probe compared to no PGE2-G. Subsequent Coomassie blue 
staining showed a band at 25kDa that was excised for tryptic digestion and mass 
spectrometric identification. 
 
 
 
Protein Identification and Validation   
Three major serine hydrolases were identified from the 25kDa band. 6-
Phosphoglucolactonase (PGLS), an enzyme involved in the pentose phosphate 
metabolism pathway; dimethylarginine dimethylaminohydrolase 2 (DDAH2), an enzyme 
responsible for hydrolysis of N(G),N(G)-dimethyl-L-arginine and N(G)-monomethyl-L-
arginine; and  platelet activating factor acetylhydrolase 1β3 subunit  (PAFAH1β3), an 
enzyme responsible for platelet activating factor (PAF) hydrolysis.  
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 Each enzyme is a member of the serine hydrolase family and all catalyze 
reactions that potentially mimic hydrolysis of PG-Gs.  First, PGLS is important in 
pentose phosphate metabolism and catalyzes the second step of the pentose phosphate 
pathway, which is the hydrolysis of 6-phosphogluconolactone to form 6-
phosphogluconate (Figure 6) (152). The hydrolysis catalyzed ring opening can potentially 
mimic components of the carboxylate and glycerol groups of PG-Gs.  Second, 
PAFAH1β3 is a catalytic subunit of the PAFAH complex, which regulates the levels of 
platelet activating factor (PAF), a pro-inflammatory molecule (153).  PAFAH1β3 
hydrolyzes the carboxylic acid group off the glycerol backbone of PAF (Figure 6).  PAF 
is very similar to lipids generated from hydrolysis of phospholipids in the bilayer.  The 
PAF molecule contains multiple structural elements that are very similar to PG-Gs, 
including a glycerol moiety that is hydrolyzed from the carboxylic acid (153). Lastly, 
DDAH2 is important in nitric oxide synthase regulation.  DDAH2 metabolizing 
N(G),N(G)-dimethyl-L-arginine and N(G)-monomethyl-L-arginine to L-citrulline and 
dimethylamine (Figure 6), which are both endogenous inhibitors of nitric oxide synthase 
(154, 155).  Though not as likely as PGLS or PAFAH1β3, substrates of DDAH2 
hydrolysis contain some elements that resemble PG-Gs.  
 
 
	   77	  
III-6. Known hydrolytic functions of PGLS, PAFAH1β3, and DDAH2 
 
 
Figure 6:  Known hydrolytic functions of PGLS, PAFAH1β3, and DDAH2. (A) 
PGLS catalyzes the pentose ring opening of 6-phosphogluconolactone at the ketone 
carbon to form 6-phosphogluconate.  (B) PAFAH1β3 hydrolyzes PAF at the sn2 position 
of the glycerol backbone to release a lysophospholipid and a free acyl group.  (C) 
DDAH2 metabolizes dimethylarginine to form dimethylamine and L-citrulline. R 
represents a long chain fatty acid.  
 
To investigate the significance of PGLS, DDAH2 and PAFAH1β3 in PGE2-G 
hydrolysis, cDNA for each protein was transfected and overexpressed in HEK293 cells. 
Importantly, these cells express no detectable levels of any of the proteins by western blot 
(Figure 7) and have low levels of hydrolase activity against PGE2-G (Figure 7). All three 
proteins were successfully transfected into HEK293 and cytosolic fraction from the 
transfected cells demonstrated high expression of each protein by western blot (Figure 7) 
compared to control.  Unfortunately, upon overexpression of DDAH2 and PAFAH1β3, 
HEK293 cytosolic fractions showed no significant increase in hydrolysis of PGE2-G 
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compared to untransfected cells (Figure 7). Comparatively, PGLS overexpression showed 
a slight increase in activity, though this increase in activity did not correlate to the 
significant increase in protein expression.  Further validation was necessary to verify 
PGLS as a PGE2-G hydrolase. 
III-7. PGLS, DDAH2 and PAFAH1β3 overexpression in HEK293 
 
 
Figure 7: PGLS, DDAH2 and PAFAH1β3 overexpression in HEK293. (A) PGE2-G 
hydrolytic activity of cell lysates obtained from HEK293 (control) or either PGLS, 
DDAH2, or PAFAH1β3 overexpressed HEK293 cells. Western blot analysis of 
overexpression in control HEK293 cells (control) and (B) PGLS, (C) DDAH2 or (D) 
PAFAH1β3 overexpressed HEK293 cells (cDNA). GAPDH Western blotting verified 
equaling protein loading (5µg per lane). Data represented as mean ± SD of n = 6 analysis.  
** <0.01 by t-test.   
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siRNA knockdowns of PGLS and PAFAH1β3 were conducted in MDA-MB-231 
cells. The levels of both PGLS and PAFAH1β3 were markedly reduced in MDA-MB-231 
cells upon transfection as determined by western blot analysis  (Figure 8). Unfortunately, 
hydrolysis of PGE2-G by cytosolic fractions obtained from either knockdown 
demonstrated no reduction in hydrolysis compared to control cells (Figure 8). Taken 
together, cDNA overexpression in HEK293 and siRNA knockdown in MDA-MB-231 do 
not support the involvement of PGLS, DDAH2 or PAFAH1β3 in prostaglandin glycerol 
ester hydrolysis. 
III-8. PGLS and PAFAH1β3 siRNA knockdown in MDA-MB-231 cells 
 
 
Figure 8: PGLS and PAFAH1β3 siRNA knockdown in MDA-MB-231 cells. PGE2-G 
hydrolytic activity of cell lysate obtained from MDA-MB-231 control (scrambled) or (A) 
PGLS deficient MDA-MB-231 (siRNA) or (B) PAFAH1β3 deficient MDA-MB-231 
(siRNA). (C) Western blot analysis of PGLS in control MDA-MB-231 (scrambled) and 
PGLS depleted cells (siRNA).  (D) Western blot analysis of PAFAH1β3 in control 
MDA-MB-231 (scrambled) and PAFAH1β3 depleted cells (siRNA). GAPDH Western 
bloting verified protein loading (5µg per lane). 
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Discussion 
Hydrolysis of prostaglandin glycerol esters has made investigation into the in vivo 
effects of these lipids difficult. Protein purification was employed in order to isolate the 
hydrolase responsible for prostaglandin glycerol ester hydrolysis from MDA-MB-231 
cells.  Competitive ABPP was utilized to determine the appropriate molecular weight of 
the serine hydrolase in the purified samples.  PGE2-G was able to inhibit the labeling of a 
protein with a molecular weight of 25kDa. In-gel tryptic digestion and proteomics 
identified three enzymes, PGLS, DDAH2, and PAFAH1β3, as potential candidates 
responsible for PG-G hydrolysis. However, cDNA overexpression and siRNA 
knockdown of these proteins determined that none were capable of hydrolyzing PG-Gs 
  Serine hydrolases have been purified from multiple sources with great success. A 
major issue that arose during the purification was the significant loss of activity due to 
the Mono-P column.   As mentioned above, samples applied to the Mono-P column 
displayed activity significantly lower then the input for the column.  This implied that the 
serine hydrolase of interest was not stable under the conditions used for this column.  
Secondly, the amount of starting material used in other purifications is usually much 
greater then 10 g.  In most cases, tissue samples or large quantities of cells are utilized as 
raw materials, which provides higher amounts of protein for isolation.  In terms of our 
purification, 10 g may not be sufficient to achieve the level of purity and stability 
necessary to isolate the major serine hydrolase of interest.   
 Protein purification is a technique that requires a number of important starting 
conditions that may be too difficult to achieve in our laboratory.  Achieving the amount 
of cells required for purification would be too costly or too difficult to achieve.  Utilizing 
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different approaches to identify the unknown serine hydrolase needs to be employed.  
One important characteristic of the PG-G hydrolase is that it belongs to the serine 
hydrolase superfamily. Understanding the nature of serine hydrolases has led to the 
development of new analytical and computational approaches to investigate the activity 
of this class of enzymes in complex biological samples (114).  ABPP coupled with multi-
dimension protein identification technology (MuDPIT) has allowed for the analysis, 
inventory, and characterization of serine hydrolases throughout multiple cancer cell lines 
(123, 156).  By understanding the relationship between enzyme activity and PG-G 
hydrolase activity, there may be a way to relate the extent of PG-G hydrolysis across a 
number of different cancer cell types and compare that to the serine hydrolase activity 
levels determined by ABPP-MuDPIT.  
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Chapter IV  
 
 
 
IDENTIFICATION OF THE MAJOR PROSTAGLANDIN GLYCEROL ESTER 
HYDROLASE IN HUMAN CANCER CELLS 
 
 
Introduction 
Endocannabinoids are a class of AA)-containing bioactive lipids that have a 
myriad of physiological functions (1, 157-162).  This diverse class of signaling molecules 
includes 2-arachidonoylglycerol (2-AG) and arachidonoylethanolamide  (AEA), which 
are produced from membrane phospholipids and initiate cellular responses through 
interactions with the cannabinoid receptors, CB1 and CB2 (1, 161, 162). Their effects are 
mitigated through metabolism by the endocannabinoid serine hydrolases, 
monoacylglycerol lipase (MAGL), α/β hydrolase domain-containing protein 6 and 12 
(ABHD6 and ABHD12), and fatty acid amide hydrolase (FAAH) (28, 35, 51, 163, 164). 
In addition to these lipases, endocannabinoids have been shown to be selective substrates 
for cyclooxygenase enzymes, particularly cyclooxygenase-2 (COX-2). Oxidation of 2-
AG by COX-2 results in the production of prostaglandin glycerol esters (PG-Gs, Figure 
1). These lipids are of growing interest because they elicit a wide array of cellular 
responses, including activation of calcium mobilization, modulation of synaptic 
transmission, induction of hyperalgesia, exacerbation of neurotoxicity and 
neuroinflammation, and elicitation of anti-inflammatory effects upon lipopolysaccharide 
stimulation (82-86, 93, 165).  
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IV-1. Biosynthesis and metabolism of 2-AG 
 
Figure 1: Biosynthesis and metabolism of 2-AG.  Following production of 2-AG, 
lipases (MAG lipase, ABHD6 and 12, CES1, and PPT1) can hydrolyze 2-AG to AA, 
which can be oxidized to form prostaglandins (PGE2 shown here). Additionally, 2-AG is 
oxidized by COX-2 to form PG-Gs (PGE2-G shown here). PG-Gs can be hydrolyzed by 
CES1, PPT1, and/or other enzymes to form the corresponding free acid prostaglandins. 
 
Investigation into the physiological relevance of PG-Gs in vivo has been a 
significant challenge due to their instability to hydrolysis in biological fluids (87). Two 
serine hydrolases have been shown to metabolize PG-Gs in human THP1 cells, 
carboxylesterase 1 (CES1) and palmitoyl-protein thioesterase 1 (PPT1).  CES1, a 
xenobiotic-metabolizing enzyme that is expressed in high amounts in the liver, 
hydrolyzes a wide array of substrates, ranging from ester and amide-containing 
xenobiotics (166), to long chain fatty acid esters and thioesters (167), and cholesteryl 
esters from lipid droplets (167, 168). Similarly, PPT1, a lysosomal hydrolase, has 
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multiple substrates; however it is predominantly responsible for the depalmitoylation of a 
number of proteins as well as hydrolysis of palmitoyl-CoA and palmitoyl thioglucoside 
(169, 170). Consistent with the wide substrate diversity exhibited by CES1 and PPT1, 
both enzymes are capable of hydrolyzing PG-Gs and 2-AG (98, 99, 171).  In THP1 
monocytes, the hydrolysis of 2-AG was almost entirely attributed to CES1, with minor 
involvement of PPT1 (98, 99, 171). Kinetic analysis of both enzymes showed greater 
catalytic turnover for 2-AG than for PG-Gs, with both enzymes exhibiting almost 2-fold 
more activity for 2-AG than for PG-Gs (99). 
We chose to investigate the hydrolase responsible for PG-G metabolism in cancer 
cell lines because of the high PGE2-G hydrolytic activity detected in preliminary 
experiments, the ease of cell maintenance, and the potential for straightforward 
biochemical and genetic manipulation. The various enzymes described above are serine 
hydrolases, so we explored the possibility that the PGE2-G hydrolase(s) in human cancer 
cells is(are) a member of this superfamily.  Serine hydrolases are a diverse class of 
enzymes that include lipases, proteases, and esterases (100, 101), and many class 
members are involved in lipid biosynthesis and metabolism (35, 51, 163, 164). A 
unifying feature of the serine hydrolase family is a catalytic mechanism that involves the 
activation of a serine nucleophile for attack on substrates containing esters, amides, or 
thioester bonds (100). This conserved mechanism has enabled the development of 
irreversible fluorophosphonate probes that can covalently modify the active site serine 
and render the enzyme catalytically inactive (101). Nomura et al. (123, 156) coupled 
fluorophosphonate probe binding with mass spectrometric proteomics techniques, known 
as ABPP-MuDPIT, to determine the relative activity levels of serine hydrolases across 
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different cancer cell lines. Utilizing these inventories and comparing the relative activities 
of individual serine hydrolases to PGE2-G hydrolase activities has allowed us to identify 
lysophospholipase A2 (LYPLA2) as the primary hydrolase responsible for PG-G 
metabolism. 
Lysophospholipases are an important class of serine hydrolases which metabolize 
lysophospholipids to form free fatty acid and the glycerol phosphate-containing head 
group and will be discussed in detail below (172). Thus, we have identified a novel 
function and substrate for LYPLA2. Specifically, we identify LYPLA2 as the serine 
hydrolase responsible for hydrolysis of PG-Gs across a number of different cancer cell 
lines. siRNA knockdown and cDNA overexpression validated the involvement of 
LYPLA2 in PG-G hydrolysis. Active enzyme was expressed and purified in E.coli, which 
allowed for kinetic evaluation of an array of different substrates.  In contrast to other PG-
G hydrolyzing enzymes, we found that LYPLA2 exerted no action on 2-AG, or AEA.  
Thus, this is the first report of a hydrolase that preferentially hydrolyzes PG-Gs with no 
effects on the endocannabinoids.  Identification and manipulation of LYPLA2 will lead 
to a better understanding of its involvement in lipid metabolism and signaling and 
facilitate the exploration of the effects of PG-Gs in both in vitro and in vivo settings. 
Lysophospholipases 
Lysophospholipid Production, Recycling and Metabolism 
Phospholipids, originally thought to only be important in membrane formation in 
cells, have emerged as an important player in a wide array of physiological and 
pathological processes.  The products of phospholipid metabolism have been shown to 
induce a wide array of different cellular responses; including signal transduction, 
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mediator formation and eicosanoid production in both normal and disease states. One 
class that has become increasingly interesting are lysophospholipids (lysoPLs). These 
molecules are a byproduct formed from the actions of phospholipases on phospholipids to 
generate polyunsaturated fatty acids.  These lysoPLs consist of one long chain fatty acid 
and one hydrophilic head group (e.g. phosphocholine, phosphoethanolamine, etc..) 
attached to the glycerol backbone. Due to the presence of both a polar head group and a 
hydrophobic tail, these lysoPLs possess detergent like properties that cells need to 
process in order to prevent toxicity (173-177). 
Two major routes of lysophospholipid detoxification have been identified in cells 
(Figure 2).  One detoxification process is known as the Lands’ cycle, which involves the 
recycling of lysoPLs by an acetyltransferase, lysophospholipid acetyltransferases  
(LPLAT), to regenerate phospholipids, which are reincorporated into the phospholipid 
bilayer (178-180).  This process has been described as the main process that gives 
membranes their lipid diversity.  By utilizing acetyl-CoAs as building blocks, a wide 
array of different lipids can be combined with these lysoPLs before being reincorporated 
into the lipid bilayer.  The second route of detoxification involves degradation of the 
lysoPLs by hydrolysis of the acyl chain to liberate the remaining fatty acid chain and the 
glycerolphosphate head group by the serine hydrolases known as the lysophospholipases 
(172).  By shifting the lysoPLs between the degradation and the recycling pathways, cells 
can control important cellular functions.   
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IV-2. Lysophospholipid biosynthesis and processing 
 
 
Figure 2:  Lysophospholipid biosynthesis and processing.  Lysophospholipids are 
produced from the hydrolysis of phospholipids from the lipid membrane by 
phospholipases to generat lysoPLs.  LysoPLs are processed in two ways; one by entering 
the Land’s Cycle which adds another fatty acid by an acetyltransferase and reincorporates 
the phospholipid into the lipid bilayer or two by further hydrolsis by lysophopholipases to 
produce a free fatty acid and a glycerolphosphate derivative 
 
 
 
Lysophospholipase activity in mammalian systems and cells has been shown to be much 
higher as compared to the phospholipase and transacylase actitivties (181-184).  This 
high activity allows cells to maintain safe levels of lipid metabolites needed for proper 
cellular function.  
  
Lysophospholipase A1 and A2   
As previously described, lysoPLs exhibit a wide array of diverse biological 
functions, because of this there are several enzymes that strictly maintain and metabolize 
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lysoPL levels, referred to as lysophospholipases, specifically lysophospholipase A1 and 
A2 (LYPLA1 and LYPLA2, respectively) (183).  These low molecular weight LYPLAs 
have been reported and purified from a number of different tissues and cells, including 
rabbit heart (185), pig gastric mucosa (186), rat liver (187), murine macrophage P388D1 
(183, 188), and human HL60 cells (189).   LYPLA1 and LYPLA2 are 25 kDa proteins 
that display similar properties; for example, both enzymes’ metabolic activities are 
independent of Ca2+, Mg2+, and EDTA and neither show any PLA transacylase activity, 
acyltransferase activity or non-specific general esterase activity (183, 186, 187, 189).  
Additionally, kinetic evaluation of these enzymes demonstrated that they are specific 
towards lysophospholipids, with no detectable levels of phospholipase activity.  
 Despite the similarity between LYPLA1 and LYPLA2, there is evidence to 
suggest that the two are actually distinct enzymes instead of splice variants or 
posttranslational modifications of the same gene.  First, antibodies that recognize 
LYPLA1 are not able to cross-react with LYPLA2, similarly LYPLA2 antibodies are not 
able to recognize LYPLA1 (183, 186, 187).  Additionally, during purification, LYPLA1 
is able to bind phosphorylcholine affinity columns while the LYPLA2 is not (183).  Also, 
upon purification LYPLA2 is much less stable compared to LYPLA1.  Furthermore, 
LYPLA1 is also able to turn over a larger variety of substrates; including 
lysophosphatidylcholine (lysoPC), lysophosphatidylethanolamine (lysoPE), 
lysophosphatidylglycerol, lysophosphatidylinositol, lysophosphatidylserine, while 
LYPLA2 prefers only the lysoPC and lysoPE containing lipids (186, 187, 189).  Finally, 
the most striking evidence is that the two proteins only share about 64% sequence 
similarity, suggesting that the two enzymes are indeed independent proteins (189).   
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 Lysophospholipases are members of the serine hydrolase family, which gives 
both enzymes very similar sequence motifs that are present across many of the serine 
proteases, lipases and esterases (172).  Much of the structural work has been done on 
LYPLA1 due to difficulties in crystallization and stability of LYPLA2.  Referring to the 
sequence of both enzymes, the serine hydrolase consensus sequence GXSXG is 
conserved in both enzymes active sites.  This sequence was verified through site directed 
mutagenesis of Ser-119 of LYPLA1 within this GXSXG motif (190).  The S119A mutant 
of this enzyme completely abolished the catalytic activity of the enzyme.  Additionally, 
the other important residues for catalytic activity were identified as Asp-174 and His-208.  
These three residues complete the classic catalytic triad (Ser-Asp-His) of serine 
hydrolases (190-192). 
Figure 3 shows the crystal structure of LYPLA1.  Secondary structural elements 
of LYPLA1 resemble the α/β hydrolase fold, which places the catalytic triad in a similar 
position as other α/β hydrolases (191, 192)., Additionally, the catalytic residues; Ser-119, 
Asp-174, and His-208, are placed close enough to place the amino acids in the 
appropriate positions to form the charge-relay network necessary for serine hydrolase 
catalysis (191, 192).  Sequence comparison of LYPLA2 and LYPLA1 show that the 
catalytic triad identified in LYPLA1 is conserved in LYPLA2, e.g. Ser-122, Asp-176, 
His-210.  This verifies that the catalytic mechanism present in LYPLA2 is similar to 
LYPLA1 and resembles the classical serine hydrolases catalytic triad (191).   
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IV-3. Crystal Structure of LYPLA1 
 
Figure 3: Crystal Structure of LYPLA1.  The catalytic triad is highlighted (orange) to 
show the charge-relay network between the serine, histidine and aspartate 
 
Tissue distribution studies demonstrated that LYPLAs are widely distributed throughout 
the body. mRNA levels demonstrated that LYPLAs are most abundant in heart, placenta, 
testis and skeletal muscle followed by liver, pancreas, kidney, brain, and lung. In contrast 
to the variable expression levels in adult, fetal distribution is more uniform throughout 
the tissues (193). The ubiquitous existence of LYPLA proteins correlates with its activity 
across a wide array of tissues and cells.  LysoPls are implicated in a mulitude of 
biological processes as well as pathological states. Exploring the roles LYPLAs play will 
be essential in understanding their physiological function and demonstrates the essential 
function these enzymes play in maintaining lysoPL levels.   
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Materials and Methods 
Chemicals, Cells and Reagents. 2-AG, AEA, PG-Gs (PGE2-1 glycerol ester, PGD2-1 
glycerol ester, PGF2α-1 glycerol ester), prostaglandin serinol amide (PGE2-SA), 
deuterated prostaglandins and PG-Gs (PGE2-d4 and PGE2-G-d5) and deuterated AA (AA-
d8) were purchased from Cayman Chemicals (Ann Arbor, MI). LC-MS solvents were 
from Fisher Scientific (Chicago, Il).  DharmaFECT 1 and methoxy fluorophosphonate 
coupled to tetramethylrhodamine (FP-TAMRA) was acquired from Thermo Scientific 
(Pittsburgh, PA).  All siRNA, Lipofactamine 2000 and Lipofectamine RNAiMAX were 
from Life Technologies (Carlsbad, CA).  Human breast cancer adenocarcinoma cell lines; 
MDA-MB-231 and MCF7, prostate cancer cell lines; PC3 and LNCaP, human embryonic 
kidney cells, HEK293, 1483 human head and neck squamous cell carcinoma and mouse 
macrophage like RAW264.7 were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA).  All cell culture media was from Gibco (Carlsbad, CA). 
Recombinant LYPLA2 cDNA and Turbofect were purchased from OriGene 
Technologies (Rockville, MD). FBS was from Atlas Biologicals (Fort Collins, CO). HIS-
Select Nickel Affinity beads are from Sigma (St. Louis, MO ). 120 mL HiPREP 16/60 
Sephacryl S-200 HR was from GE Healthcare (Piscataway, NJ). Luna liquid 
chromatography reverse phase C18 column was from Phenomenex (Torrance, CA). 
Culture Conditions. MDA-MB-231, MCF7, LNCaP, and HEK293 cells were maintained 
as an adherent culture in RPMI medium supplemented with 10% (v/v) fetal bovine serum 
(FBS) at 37°C and 5% CO2. PC3 cells were grown in DMEM/F12 supplemented with 
10% (v/v) FBS.  RAW 264.7 mouse macrophage cells were maintained in high glucose 
DMEM supplemented with 10% FBS. All cells were grown to no more than 75% 
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confluence. 
siRNA Knockdown of LYPLA2 in Multiple Cancer Cell Types. MDA-MB-231 cells were 
plated at 1.0 x 106 cells per 100 mm2 and allowed to incubate for 24 h to 40-60% 
confluence.  siRNA was introduced into the cells as a complex with DharmaFECT 1 
according to manufacturer’s recommendations.  Briefly, siRNA/DharmaFECT complexes 
were formed for 20 min in serum free OPTIMEM1.  RPMI medium from each plate was 
removed and replaced with 5 mL of serum-free OPTIMEM1 medium followed by 
addition of 1 mL of transfection solution.  Cells were cultured for 24 h at 37°C.  Medium 
was subsequently replaced with RPMI containing 10% FBS and incubated at 37°C for an 
additional 48 h before harvesting. 
 PC3 cells were plated at 1.0 x 106 cells per 100 mm2 and allowed to incubate for 
24 h to give 40-60% confluence. Complex formation with siRNA and Lipofectamine 
2000 was performed according to manufacturer’s recommendations.  Briefly, 
siRNA/Lipofectamine complexes were formed for 20 min in serum free OPTIMEM1.  
The medium in each plate was removed and replaced with serum-free OPTIMEM1 
medium followed by addition of 1 mL of transfection solution.  The cells were cultured 
for 8 h at 37°C.  The medium was subsequently replaced with DMEM/F12 supplemented 
with 10% (v/v) FBS.  Cells were incubated at 37°C for an additional 48 h before 
harvesting. 
LNCaP cells were plated at 1.0 x 106 cells per 100mm2 and allowed to incubate 
for 24 h to 40-60% confluence. Complex formation with siRNA and Lipofectamine 
RNAiMAX was performed according to manufacturer’s recommendations.  Briefly, 
siRNA/Lipofectamine complexes were formed for 5 min in serum-free OPTIMEM1.  
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One mL of transfection solution was added to each plate, and the cells were cultured for 
72 h at 37°C before harvesting. 
LYPLA2 cDNA Overexpression in HEK293 Cells. HEK293 cells were plated at a density 
of 3 x 105 cells per well in a 6 well plate in RPMI medium supplemented with 10% FBS 
and incubated for 24 h at 37°C. cDNA was prepared by adding 45 µL of Turbofect to 250 
µL of OPTIMEM1 followed by 15 µL (1.5 µg) of cDNA. The cells were incubated at 
room temperature for 30 min.  cDNA solution was added to each well drop-wise, and 
cells were incubated at 37°C for an additional 48 h before harvesting.    
Preparation of Cell Lysates. Cells were harvested by scraping, pelleted by centrifugation, 
and washed once with phosphate-buffered saline.  The cells were resuspended in 500 µL 
ice-cold 25 mM Tris buffer (pH 7.5) containing 0.1 mM of both EDTA and DTT.  Cells 
were lysed by sonication (Virsonic Cell Disrupter model 16-850, 10 x 10 sec pulses at 
relative output of 0.5, on ice), and the cytosolic fractions were separated by centrifugation 
(100,000 x g for 1 h).  Protein concentrations were determined using the BCA reagent kit 
according to the manufacturer’s instruction (Pierce, Rockford Il).   
PG-G Hydrolase Assay. Hydrolytic activity was determined by adding 10 nmol of PGE2-
G to 100µL cell lysates at 37°C.  Reactions were quenched after 2 h by addition of 1 mL 
of ethyl acetate containing deuterated internal standard (PGE2-d4). The organic layer was 
removed, evaporated to near dryness under nitrogen, and reconstituted with 50% 
methanol. Samples were analyzed by LC-MS/MS for the hydrolytic product, PGE2, 
which was quantified against the internal standard using stable isotope dilution.  
Serine Hydrolase Inhibition. The general serine hydrolase probe, FP-TAMRA was used 
to determine the involvement of serine hydrolases in the metabolism of PG-Gs. FP-
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TAMRA (100 nM) or DMSO was added to 100 uL of MDA-MB-231 cytosol and 
allowed to incubate for 30 min at 37°C. PG-G hydrolase activity was determined as 
described above, except that samples were incubated from 0 to 60 min to obtain a full 
hydrolysis time course.    
Western Blot Analysis. Protein expression was determined by western blot analysis.  
Samples were separated by sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE).  Then, proteins were transferred to a nitrocellulose membrane 
and probed with either rabbit anti-LYPLA2 (1:500 v/v), rabbit anti-LYPLA1 (1:500 v/v) 
or anti-COX-2 (1:1000 v/v) and goat anti-β-actin (1:5000, v/v) overnight at 4°C.  
Membranes were washed and incubated with IR-visible anti-rabbit or anti-goat secondary 
antibodies (1:5000, v/v).  Blots were visualized using an Odyssey IR Imager. 
Recombinant protein E.coli Expression. Full-length LYPLA2 or LYPLA1 was cloned 
into an untagged (pC6H) or a hexahistidine-tagged (p6Hb) vector using overlap PCR and 
isothermal assembly (194).  These constructs were subsequently transformed into BL21 
Rosetta E. coli cells (Catalog # 71402, EMD Millipore) for protein expression.  Large-
scale expression was carried out in 10 L of autoinduction medium (195) at 37°C 
overnight.   
His-tagged LYPLA2 E.coli Purification. All purification was performed at 4°C.  E.coli 
cell pellets were resuspended in 20 mM sodium phosphate buffer (pH 7.4) containing 500 
mM NaCl, 20 mM imidazole, and 0.1mM DTT.  Cells were lysed by sonication (10 x 10 
sec pulses at relative output of 0.5, on ice) and the cytosolic fraction was separated by 
centrifugation (100,000 x g for 1 h). HIS-Select Nickel Affinity beads pre-equilibrated 
with Buffer A (20 mM sodium phosphate buffer (pH 7.4), 500 mM NaCl, 20mM 
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imidazole, and 0.1 mM DTT) were added to the cytosolic fraction, and protein was bound 
overnight.  Beads were packed into a column and washed with 4 column volumes of 
Buffer A.  His tagged protein was eluted by linear gradient from 0 to 100% Buffer B (20 
mM sodium phosphate buffer (pH 7.4), 500 mM NaCl, and 500 mM imidazole).  Eluted 
protein was collected and concentrated using a Millipore 3000 MWCO centrifugal filter.  
Protein was loaded onto a 120 mL HiPREP 16/60 Sephacryl S-200 HR size exclusion 
column pre-equilibrated with 2 column volumes of running buffer (Tris buffer (pH 7.5)), 
0.1 mM EDTA, 0.1 mM DTT).  The column was was eluted with 1 column volume of 
running buffer at a flow rate of 0.5 mL/min, protein was collected, and purity was 
validated by SDS-PAGE.   
LYPLA2 Kinetic Analysis. Hydrolysis reactions with recombinant LYPLA2 (100 nM 
protein) were performed in 25 mM Tris buffer (pH 7.5) with 0.1 mM EDTA and 0.1 mM 
DTT.  Substrates were added at varying concentrations, ranging from 0-200 µM.  After 
preincubation of LYPLA2 for 5 min at 37°C, reactions were initiated with the addition of 
substrate.  Reactions were quenched after 5 min with 1 mL of ethyl acetate containing 20 
ng/mL of either PGE2-d4 (for PGE2-G and PGD2-G), PGF2α-d4 (for PGF2α-G), AA-d8 
(for 2-AG and AEA) or l7:0 lysoPC (for stearoyl and palmitoyl lysoPC). 5 minutes was 
optimal for determining kinetic parameters for substrates analyzed. The organic layer was 
collected and dried to completion under nitrogen.  Samples were reconstituted in 50% 
methanol and analyzed by LC-MS/MS. Kinetic parameters were determined by 
performing non-linear regression analysis using a Michaelis-Menton equation with Prism 
Graphpad version 5.0d. 
Hydrolytic Activity of LYPLA2 Following Small Molecule Inhibition. Inhibition reactions 
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were conducted in 25 mM Tris buffer (pH 7.5) with 0.1 mM EDTA and 0.1 mM DTT 
containing 100 nM of recombinant LYPLA2.  100 µL of protein was preincubated with 
0-100 µM of either Compound 1 or 21 (131), or the PGE2-G structural analog 
(prostaglandin E2 serinol amide, PGE2-SA) for 5 min. Reactions were initiated by 
addition of 5 µM of PGE2-G and then quenched after 5 min with 1 mL of ethyl acetate 
containing 20 ng/mL of PGE2-d4.  The organic layer was evaporated to dryness under 
nitrogen, reconstituted in 50% methanol, and analyzed by LC-MS/MS for PGE2.   
LYPLA2 inhibition in RAW 264.7 murine macrophage-like cells. The effects of LYPLA2 
inhibition on PG-G production were tested by exposure of cells to Compound 1.  RAW 
264.7 cells were plated at 3 x 106 cells per 100 mm2 plate and incubated for 24 h in 
DMEM supplemented with 10% FBS.  Medium was replaced with serum-free DMEM 
containing either 1 µg/mL of lipopolysaccharide (LPS), 10 µM Compound 1, or a 
combination of both, and allowed to incubate for 6 h, Cells treated with LPS were then 
spiked with 5 µM of ionomycin (Calbiochem) for 45 min.  Ionomycin stimulates the 
production of 2-AG and AA from endogenous sources (196).  Lipids were extracted from 
the cell medium by addition of 2x volume of ethyl acetate containing PGE2-d4, PGE2-G-
d5 and AA-d8 internal standards.  The organic layer was dried under nitrogen, and the 
residue was reconstituted in 50% methanol for analysis of PGs, PG-Gs, and AA by LC-
MS/MS.   
LYPLA2 inhibition in 1483 Human Squamous Cell Carcinoma. The effects of LYPLA2 
inhibition on PG-G production were tested by exposure of cells to Compound 1.  1483 
cells were plated at 3 x 106 cells per 100 mm2 plate and incubated for 24 h in RPMI 
supplemented with 10% FBS.  Medium was replaced with serum-free RPMI containing 
	   97	  
10 µM Compound 1 and allowed to incubate for 2 h, Cells were then spiked with 5 µM of 
ionomycin for 45 min. Lipids were extracted from the cell medium by addition of 2x 
volume of ethyl acetate containing PGE2-d4, PGE2-G-d5 and AA-d8 internal standards.  
The organic layer was dried under nitrogen, and the residue was reconstituted in 50% 
methanol for analysis of PGs, PG-Gs, and AA by LC-MS/MS.   
LC-MS Analytical Procedures. Analysis of prostanoids was accomplished by reverse 
phase chromatography followed by mass spectrometric detection by selected reaction 
monitoring (SRM) using a Shimadzu LC-20 HPLC system coupled to an Applied 
Biosystems 3200 QTrap mass spectrometer.  Separation of PGs and LysoPCs was 
achieved by gradient elution of a Phenomenex Luna C18 column (50mm x 2.0 mm, 3µm 
particle size). Solvent A was HPLC grade water with 0.1% formic acid, and solvent B 
was acetonitrile (ACN) with 0.1% formic acid.  Samples were injected onto the column 
with a starting condition of 80% solvent A and 20% solvent B at a flow rate of 0.5 
mL/min.  A linear gradient of increasing solvent B to 98% was run over 2 min and then 
held for 1.5 min.  SRM transitions were as follows; PGE2 transition m/z 351.3→271.2, 
PGE2-d4 m/z 355.3→275.2, 18:0 lysoPC m/z 524.3→184.3, 17:0 lysoPC m/z 
510.3→184.3, 16:0 lysoPC m/z 496.3→184.3. 
 Resolution of PGs and PG-Gs was accomplished with a gradient formed between 
solvent A, HPLC grade water with 5mM ammonium acetate (pH 3.6), and solvent B, 
ACN supplemented with 6% (v/v) of solvent A.  Samples were injected onto the column 
with a starting condition of 70% solvent A and 30% solvent B at a flow rate of 0.6 
mL/min.  A linear gradient of increasing solvent B to 100% was run over 3.1 min and 
then held for 1.8 min. SRM transitions were as follows; PGE2-G transition m/z 
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444.3→391.3, PGE2-G-d5 m/z 449.3→396.3, PGE2 m/z 370.3→317.2, PGE2-d4 m/z 
374.3→321.2. 
Resolution of AA was achieved by gradient elution.  Solvent A was HPLC grade 
water with 80 µM silver acetate, and solvent B was methanol with 118 µM silver acetate.  
Samples were injected onto the column with a starting condition of 80% solvent A and 
20% solvent B at a flow rate of 0.4 mL/min.  A linear gradient of increasing solvent B to 
100% was run over 1 min and then held for 2 min. SRM transition was as follows; AA 
m/z 518.9→411.1, AA-d8 m/z 526.9→419.1. 
 
Results 
Characterization of PGE2-G Hydrolysis in Cancer Cells 
MDA-MB-231 breast cancer cells were initially tested for hydrolytic activity by 
quantitatively monitoring the formation of PGE2 from exogenously provided PGE2-G by 
LC-MS/MS.  As demonstrated in Chapter III, cytosolic fractions showed PGE2-G 
hydrolase activity that was linear with time (Figure 2 in Chapter III,).  It is important to 
note that MDA-MB-231 cells do not express detectable levels of MAGL (123). Initial 
studies demonstrated that the majority of hydrolytic activity was present in the cytosol, 
with no activity detectable in the membrane fraction (Figure 2 in Chapter III). 
Importantly, serine hydrolase inventories have been identified and published for multiple 
cancer cell lines, including MDA-MB-231.  In Chapter III, we determined that the serine 
hydrolase family was responsible for PGE2-G hydrolysis.  
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IV-4. PGE2-G hydrolase activities in human cancer cells 
 
Figure 4:  PGE2-G hydrolase activities in human cancer cells. PGE2-G hydrolytic 
activity was assessed across multiple human cancer cell types.  
 
 Nomura et al. recently profiled serine hydrolases in a series of human cancer cell 
lines (123, 156). The serine hydrolase proteome was enriched by covalently labeling the 
enzymes with fluorophosphonate molecules bound to biotin followed by avidin 
chromatography.  The purified serine hydrolases were identified by multidimensional 
liquid chromatography mass spectrometry-based proteomic analysis of tryptic digests. 
Spectral counting, revealed the relative levels of serine hydrolases across a number of 
aggressive and non-aggressive cancer cell types (123, 156). Utilizing the cancer cell types 
investigated in these serine hydrolase inventories, we quantified PGE2-G hydrolysis by 
the cytosolic fractions of two breast cancer cell lines, MDA-MB-231 and MCF7, and two 
prostate cancer cell lines, PC3 and LNCaP. Figure 4 demonstrates that LNCaP cells 
exhibited the lowest hydrolytic activity, while PC3 cells displayed the highest rate of 
PGE2-G hydrolysis. All breast cancer cell lines tested, including MCF7, MDA-MB-231 
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and MDA-MB-231 cells passaged through a mouse fat pad (mfp), exhibited intermediate 
levels of activity. We compared both MDA-MB-231 cell types because MDA-MB-231 
mfp cells express MAGL whereas the MDA-MB-231 do not (123).  By comparing the 
PGE2-G hydrolytic activity across the cell lines to published inventories of over 60 
cytosolic serine hydrolases (Supplemental Table 1) (123, 156), we were able to identify 
one enzyme, acyl-protein thioesterase 2 (APT2), also referred to lysophospholipase A2 
(LYPLA2), that correlated across all data sets. 
 
LYPLA2 Involvement in PGE2-G Hydrolysis 
To investigate the role LYPLA2 plays in PGE2-G hydrolysis, siRNA knockdown 
of enzyme expression was initially conducted in MDA-MB-231 cells. The level of 
LYPLA2 was markedly reduced in MDA-MB-231 cells upon transfection with siRNA as 
determined by western blot analysis  (Figure 5A). Cytosolic fractions obtained from 
MDA-MB-231 cells following LYPLA2 knockdown displayed a 60% reduction in 
hydrolysis of PGE2-G compared to control cells (Figure 5B). The effect of LYPLA2 on 
PGE2-G hydrolysis was also reduced upon siRNA transfection in PC3 and LNCaP cell 
lines (Supplemental Figure 1). MDA-MB-231 cells were transfected with a second 
siRNA to account for potential off-target effects of the initial siRNA. PC3-, MDA-MB-
231-, and LNCaP-transfected cell lines displayed significant decreases in the level of 
LYPLA2 as determined by western blot analysis (Supplemental Figure 1B).  
Comparisons of PGE2-G hydrolytic activity from cytosol obtained from control and 
LYPLA2 knockdown cells (Supplemental Figure 1A) demonstrated a reduction in 
hydrolysis of 60% in PC3 cells and 50% in MDA-MB-231 cells, while siRNA 
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knockdown in LNCaP cells displayed a minor decrease of 25% in hydrolytic activity. 
This minor decrease in LNCaP hydrolytic activity may be due to lower expression levels 
of LYPLA2 (123, 156), which would correlate with smaller decreases in activity.  
However, cells that demonstrate high levels of hydrolytic activity are the most affected 
by siRNA knockdown of LYPLA2.  For example, PC3 and MDA-MB-231 cells show the 
highest level of hydrolytic activity and upon LYPLA2 knockdown there is a 60% 
reduction in activity. Taken together, siRNA knockdown across multiple cell lines 
supports the involvement of LYPLA2 in the major PG-G hydrolysis enzyme in cells with 
high hydrolytic activity.  
 To further validate LYPLA2 involvement in PGE2-G hydrolysis, cDNA for 
LYPLA2 was transfected and overexpressed in HEK293 cells. Importantly, these cells 
express no detectable levels of LYPLA2 by western blot (Figure 5C) and have low levels 
of hydrolase activity against PGE2-G (Figure 5D). LYPLA2 was successfully transfected 
into HEK293 cells, and the cytosolic fraction from the transfected cells demonstrated 
high expression of LYPLA2 by western blot (Figure 5C) compared to control cells.  
Importantly, upon overexpression of LYPLA2, HEK293 cytosolic fractions showed a 
significant increase in PGE2-G hydrolytic activity compared to fractions from 
untransfected cells (Figure 5D). Combined with siRNA knockdown data, the 
overexpression data confirm LYPLA2 as the main serine hydrolase responsible for PGE2-
G hydrolysis in highly hydrolytically active multiple cancer cell lines.  
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IV-5. LYPLA2 siRNA knockdown in MDA-MB-231 cells and LYPLA2 overexpression in HEK293 
 
Figure 5: LYPLA2 siRNA knockdown in MDA-MB-231 cells and LYPLA2 
overexpression in HEK293. (A) Western blot analysis of LYPLA2 in control MDA-
MB-231 cells (scrambled) and LYPLA2-depleted cells (siRNA). β-actin Western blotting 
verified uniform protein loading (5 µg per lane). (B) PGE2-G hydrolytic activity of 
cytosol obtained from MDA-MB-231 control cells (scrambled) or LYPLA2-deficient 
MDA-MB-231 cells (siRNA). (C) Western blot analysis of LYPLA2 in control HEK293 
cells (control) and LYPLA2-overexpressing HEK293 cells (cDNA). β-actin Western 
blotting verified equaling protein loading (5 µg per lane).  (D) PGE2-G hydrolytic activity 
of cytosol obtained from HEK293 (control) or LYPLA2-overexpressing (cDNA) cells. 
Data are presented as the mean ± S.D. of triplicate analyses.  **** indicates p < 0.001 by 
t-test.   
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LYPLA1 Involvement in PGE2-G Hydrolysis 
 LYPLA2 is a member of the serine hydrolase family responsible for 
lysophospholipid metabolism.  Additionally, there is a second isoform present in all 
tested cancer cell lines, named lysophospholipase A1 (LYPLA1).  Like LYPLA2, this 
enzyme is responsible for hydrolysis of lysophospholipids.  To investigate the role 
LYPLA1 plays in PGE2-G hydrolysis, siRNA knockdown of LYPLA1, LYPLA2 and a 
combination of both enzymes was conducted in MDA-MB-231 cells. The levels of 
LYPLA1 and LYPLA2 were markedly reduced in MDA-MB-231 cells upon transfection 
with siRNA as determined by western blot analysis  (Figure 6A and B). Cytosolic 
fractions obtained from MDA-MB-231 cells following LYPLA1 knockdown displayed a 
minor reduction in hydrolysis of PGE2-G compared to control cells (Figure 6). Similar to 
above, cytosolic fractions from MDA-MB-231 cells following LYPLA2 knockdown 
displayed a significant reduction in hydrolysis of PGE2-G compared to control cells. 
Additionally, cytosolic fractions from cells following knockdown of both LYPLA1 and 
LYPLA2 together displayed a significant reduction in hydrolysis of PGE2-G compared to 
control cells, however there was no additive effects compared to LYPLA2 knockdown 
alone.   
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IV-6. LYPLA1 and LYPLA2 siRNA knockdown in MDA-MB-231 cells. 
 
Figure 6: LYPLA1 and LYPLA2 siRNA knockdown in MDA-MB-231 cells. (A) 
Western blot analysis of LYPLA1 in control MDA-MB-231 cells (scrambled), LYPLA1-
depleted cells (siRNA LYPLA1) and LYPLA1/LYPLA2-depleted cells (combination). β-
actin Western blotting verified uniform protein loading (5 µg per lane). (B) Western blot 
analysis of LYPLA2 in control MDA-MB-231 cells (scrambled), LYPLA1-depleted cells 
(siRNA LYPLA1) and LYPLA1/LYPLA2-depleted cells (combination). β-actin Western 
blotting verified uniform protein loading (5 µg per lane). (C) PGE2-G hydrolytic activity 
of cytosol obtained from MDA-MB-231 control cells (scrambled), LYPLA1-deficient 
(LYPLA1), LYPLA2-deficient (LYPLA2), or LYPLA1/LYPLA2-deficient MDA-MB-
231 cells (combination). Data are presented as the mean ± S.D. of triplicate analyses. 
 
 
To further validate whether LYPLA1 is involved in PGE2-G hydrolysis, cDNA for 
LYPLA1 was transfected and overexpressed in HEK293 cells. LYPLA1 was successfully 
transfected into HEK293 cells, and the cytosolic fraction from the transfected cells 
demonstrated high expression of LYPLA2 by western blot (Figure 7) compared to control 
cells.   
Importantly, upon overexpression of LYPLA1, HEK293 cytosolic fractions 
showed no significant increase in PGE2-G hydrolytic activity compared to fractions from 
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untransfected cells (Figure 5). Unlike the siRNA knockdown data, the overexpression 
data does not confirm LYPLA1 an additional serine hydrolase responsible for PGE2-G 
hydrolysis in highly hydrolytically active cancer cell lines.  
IV-7. LYPLA1 and LYPLA2 overexpression in HEK293 
 
Figure 7: LYPLA1 and LYPLA2 overexpression in HEK293.  Western blot analysis 
of (A) LYPLA1 and (B) LYPLA2 in control HEK293 cells (control), LYPLA1-
overexpressing (LYPLA1) and LYPLA2-overexpressing HEK293 cells (LYPLA2). 
GAPDH Western blotting verified equaling protein loading (5 µg per lane).  (B) PGE2-G 
hydrolytic activity of cytosol obtained from HEK293 (control), LYPLA1-overexpressing 
(LYPLA1)  or LYPLA2-overexpressing (LYPLA2) cells. Data are presented as the mean 
± S.D. of n = 6 per analyses.  **** indicates p < 0.001 by t-test. N/S = not significant 
 
Expression of Recombinant Human LYPLA1 and LYPLA2 
 Further validation for LYPLA1 involvement was needed in order to determine 
whether it is a serine hydrolase involved in PG-G hydrolysis.  Expression of human 
LYPLA1 in E.coli caused no significant increase in PGE2-G hydrolysis while expression 
of human LYPLA2 in E.coli significantly increased PGE2-G hydrolytic activity as 
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compared to the activity in wild-type cells (Figure 8).  This data in combination with the 
siRNA knockdown and cDNA overexpression confirms that LYPLA1 is not responsible 
for PGE2-G hydrolysis in cells.  Importantly, siRNA knockdown, cDNA overexpression 
and expression in E.coli all confirm that LYPLA2 is the hydrolase responsible for 
hydrolysis in human cells. 
IV-8. Production of recombinant human LYPLA1 and LYPLA2 by overexpression in E.coli 
 
Figure 8: Production of recombinant human LYPLA1 and LYPLA2 by 
overexpression in E.coli. PGE2-G hydrolytic activity of cytosol obtained from wild-type 
E. coli and E. coli overexpressing recombinant human LYPLA1 or LYPLA2. 
 
 
Expression, Isolation, and Activity of Recombinant Human LYPLA2  
 Having demonstrated that only LYPLA2 is involved in PGE2-G hydrolysis, we 
next aimed to elucidate the biochemical activities of this serine hydrolase utilizing 
expressed and purified his-tagged recombinant hLYPLA2. Expression of LYPLA2 or 
his-tagged LYPLA2 in E.coli, significantly increased PGE2-G hydrolytic activity as 
compared to the activity in wild-type cells (Figure 9), further confirming LYPLA2 is 
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capable of hydrolyzing PGE2-G. Purification of the his-tagged hLYPLA2 (Figure 9), 
revealed a single band at 25kDa, on Coomassie blue-stained gels and Western blots, 
correlating to the predicted molecular weight of LYPLA2.  On the basis of Coomassie 
blue staining, the expressed his-tagged hLYPLA2 was >95% pure.  
 
IV-9. Production of recombinant his-tagged human LYPLA2 by overexpression in E.coli 
 
Figure 9:  Production of recombinant his-tagged human LYPLA2 by overexpression 
in E.coli. (A) PGE2-G hydrolytic activity of cytosol obtained from wild-type E. coli and 
E. coli overexpressing recombinant human LYPLA2, and recombinant his-tagged human 
LYPLA2. (B) Coomassie blue staining (left) and Western blot analysis of LYPLA2 
(center) and His tag (right) of purified, recombinant his-tagged LYPLA2 produced by E. 
coli.  
 
Lysophospholipids, Endocannabinoids, and Prostaglandin Glycerol Esters as 
Substrates of Recombinant LYPLA2: A Kinetic Analysis 
Because recombinant human LYPLA2 could hydrolyze PGE2-G to its free acid 
prostaglandin, we next evaluated kinetics of LYPLA2 hydrolysis against an array of 
substrates, including multiple PG-Gs (PGE2-G, PGD2-G, PGF2α-G), endocannabinoids 
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(2-AG and AEA), and lysophospholipids (palmitic (16:0) or stearic (18:0) 
lysophosphatidylcholine (lysoPC)). Analysis of substrate concentration-velocity plots 
(Figure 10) yielded steady-state Michaelis-Menton kinetic parameters (Table 1) for 
LYPLA2 hydrolytic activity against all substrates tested.  
 
Table 1:  Kinetic parameters for hydrolysis of multiple lipid substrates by recombinant 
human LYPLA2 
IV-1. Kinetic parameters for hydrolysis of multiple lipid substrates by recombinant human LYPLA2 
 
 Initially, we determined activity towards lysophospholipid substrates and found that the 
catalytic efficiencies of LYPLA2 for palmitoyl and stearoyl lysoPC (Kcat/Km = 4.0 and 
5.6 min-1µM-1, respectively) were comparable to published values (172). Compared to its 
activity with lysophospholipids, LYPLA2 had lower hydrolytic efficiency towards PG-
Gs.  Interestingly, LYPLA2 showed a greater catalytic efficiency for PGE2-G (Kcat/Km = 
1.1 min-1µM-1) than for PGF2α-G and PGD2-G (Kcat/Km = 0.44 and 0.14 min-1µM-1, 
respectively). Importantly, LYPLA2 did not display any catalytic activity against the 
endocannabinoids, 2-AG and AEA. 
 
 
Substrate  
Kcat 
 (min-1) 
Km  
(µM) 
Kcat/Km  
(min-1 µM-1) 
PGE2-G 14.1 ± 0.4 13 ± 1.1 1.08 
PGF2α-G 2.2 ± 0.3 5 ± 1.1 0.44 
PGD2-G 9.5 ± 1.6 67 ± 14 0.14 
LysoPC (16:0) 33.3 ± 1.7 8.3 ± 1.0   4.0 
LysoPC (18:0)  44.3 ± 10.2 7.8 ± 4.4 5.6 
2-AG N/A N/A N/A 
AEA N/A N/A N/A 
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IV-10. LYPLA2 hydrolytic activity against multiple lipid substrates 
 
 
 
Figure 10: LYPLA2 hydrolytic activity against multiple lipid substrates. Substrate 
concentration (pmol) vs. reaction velocity (pmol/min) plots for recombinant his-tagged 
LYPLA2.  Data are presented as the mean ± S.D. of triplicate analyses. 
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Inhibition of Recombinant LYPLA2 Results in Decreased Hydrolysis of PG-Gs 
 To understand the effect LYPLA2 has in a biological system requires LYPLA2-
specific inhibitors.  Fortunately, selective inhibitors for LYPLA2 have been discovered 
and evaluated by Abibekian et al. (131).  Their inhibitors were identified by high-
throughput competitive activity-based protein profiling and showed high specificity for 
LYPLA2 as compared to other lysophospholipases. In the same study, Abibekian et al. 
also discovered a lysophospholipase A1 specific inhibitor (131). As stated above, 
lysophospholipase A1 (LYPLA1) is a homologue which shares 60% sequence homology 
with LYPLA2 (172) but utilizes a wider array of substrates. Inhibitors were named 
Compound 1 (LYPLA2-specific inhibitor) and Compound 21 (LYPLA1-specific 
inhibitor). We assessed their effects (Figure 9), on the hydrolytic activity of LYPLA2. 
Demonstrated in Figure 11, Compound 1 (the selective LYPLA2 inhibitor) has an IC50  of 
904 nM for the inhibition of PGE2-G hydrolysis, comparable to previously reported 
values (510 nM) for the inhibition of hydrolysis of a fluorescence substrate, resorufin 
acetate (131); Compound 21 (a selective LYPLA1 inhibitor), however, did not affect 
LYPLA2 activity. A PGE2-G structural analog, PGE2-SA, was also assessed for LYPLA2 
inhibition. Interestingly, PGE2-SA had no effect on the hydrolysis of PGE2-G, indicating 
the enzyme may have a very tight requirement for substrate binding.  
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IV-11. Inhibition of LYPLA2 by small molecule inhibitors 
 
Figure 11: Inhibition of LYPLA2 by small molecule inhibitors.  (A) Chemical 
structures and IC50 values for Compound 1(LYPLA2 specific inhibitor), Compound 21 
(LYPLA1 specific inhibitor), and PGE2-SA (structural analog of PGE2-G). (B) Inhibition 
curves of LYPLA2-mediated hydrolysis of PGE2-G by Compound 1 (◼), Compound 21 
(●), and PGE2-SA (▲). Data are presented as the mean ± S.D. of triplicate analyses. 
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LYPLA2 Inhibition Reduced PG-G Hydrolysis in RAW 264.7 Murine Macrophage-
Like Cells 
To assess the physiological relevance of PG-G hydrolysis by LYPLA2, murine 
RAW264.7 macrophage-like cells were stimulated to produce PGE2-G and PGD2-G by 
priming cells with LPS (1 µg/mL) to induce expression of COX-2 (Figure 12) followed 
by treatment with the calcium ionophore ionomycin (5µM) to promote release of 2-
AG/AA. We determined whether inhibition of LYPLA2 by Compound 1 could affect the 
amount of PG-Gs produced in stimulated RAW264.7 cells. Upon simulation, RAW264.7 
cells produced high levels of PGD2 and PGE2 and much lower levels of PGD2-G and 
PGE2-G, as previously reported (Figure 12). Pretreatment of stimulated RAW264.7 cells 
with 10 µM of the LYPLA2-specific inhibitor prior to addition of ionomycin, increased 
the levels of PGD2/PGE2-G in the medium compared to those in the medium of 
uninhibited cells (40 vs 26 pmol). A concomitant decrease in PGD2/PGE2 was not 
observable because of the large excess of prostaglandins to PG-Gs in stimulated RAW 
cells. 
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IV-12. LYPLA2 inhibition significantly increases endogenous levels of PGE2-G/PGD2-G formed in RAW264.7 murine 
macrophage-like cells 
 
Figure 12: LYPLA2 inhibition significantly increases endogenous levels of PGE2-
G/PGD2-G formed in RAW264.7 murine macrophage-like cells.  Cells were treated 
with LPS (1 µg/mL) in the presence of absence of a LYPLA2-specific inhibitor (10 µM) 
for 6 h in serum free medium followed by treatment with ionomycin (5 µM) for 45 min.  
The culture medium was removed and lipids extracted for LC-MS/MS analysis for PGE2-
G/PGD2-G (A), PGE2/PGD2 (B) and AA (C).  (D) Western blot analysis of untreated and 
treated RAW264.7 macrophages confirmed the expression of COX-2 and LYPLA2 in 
cells.  β-actin western blot verified protein loading (10 µg per lane). Data are presented as 
the mean ± S.D. of triplicate analyses. ** indicates p < 0.01 
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LYPLA2 Inhibition Reduced PG-G Hydrolysis in 1483 Human Squamous Cell 
Carcinoma Cells 
To assess the physiological relevance of PG-G hydrolysis by LYPLA2 in a human 
cell setting, 1483 cancer cells were utilized because they constitutively express COX-2 
(Figure 13).  Ionophore ionomycin (5µM) was added to promote release of 2-AG/AA. 
We determined whether inhibition of LYPLA2 by Compound 1 could affect the amount 
of PG-Gs produced in 1483 cancer cells. Upon release of 2-AG and AA, 1483 cancer 
cells produced levels of PGD2 and PGE2 (70 pmol), but at significantly lower levels then 
those observed in RAW264.7 cells (1500 pmol).  Interestingly, comparable levels of 
PGF2α were also produced (30 pmol) implying that 1483 express high levels of both EP 
and FP synthases. Additionally, no detectable levels of PGD2-G and PGE2-G were 
observed (data not shown), however there are observable levels of PGF2α-G. Pretreatment 
of 1483 cancer cells with 10 µM of the LYPLA2-specific inhibitor prior to addition of 
ionomycin, increased the levels PGF2α-G in the medium compared to those in the 
medium of uninhibited cells (7 vs. 4 pmol). A concomitant decrease in PGF2α was not 
observable because of the large excess of prostaglandins to PG-Gs in these cells.  Finally, 
no change in detectable levels of PGD2-G and PGE2-G was observed, implying that there 
may be a need to understand the relationship between PGH2 and PGH2-G and these 
lipids’ interactions with prostaglandin synthases.   
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IV-13. LYPLA2 inhibition significantly increases endogenous levels of PGF2α-G formed in 1483 human squamous cell 
carcinomas 
 
Figure 13:  LYPLA2 inhibition significantly increases endogenous levels of PGF2α-G 
formed in 1483 human squamous cell carcinomas.  Cells were treated with LYPLA2-
specific inhibitor (10 µM) for 2 h in serum free medium followed by treatment with 
ionomycin (5 µM) for 45 min.  The culture medium was removed and lipids extracted for 
LC-MS/MS analysis PGE2/PGD2 (A), PGF2α-G (A), PGF2α (A) and AA (C).  (B) Western 
blot analysis of untreated and treated 1483 human caner cells confirmed the constitutive 
expressionion of COX-2 and LYPLA2 in cells.  β-actin western blot verified protein 
loading (10 µg per lane). Data are presented as the mean ± S.D. of quadruplicate 
analyses. * indicates p < 0.01 
 
 
  
	   116	  
Discussion 
 Endocannabinoids are lipid mediators that elicit a variety of physiological effects, 
including analgesia and suppression of inflammation (1, 162, 197). COX-2 oxygenates 2-
AG to form PG-Gs, which display effects that are frequently opposite those of 
endocannabinoids, e.g., hyperalgesia and neuroinflammation (82-86, 93, 165). However, 
complete elucidation of the effects of PG-Gs in vivo has been challenging due to their 
hydrolytic instability (87). The present studies have identified a serine hydrolase, 
LYPLA2, as a major enzyme responsible for PGE2-G hydrolysis in human cancer cells. 
 LYPLA2 was expressed in E. coli and purified to apparent homogeneity in order 
to determine its specific activity against a range of substrates. LYPLA2 exhibited higher 
catalytic efficiency against lysophospholipids than against PG-Gs. Among the PG-Gs 
tested, PGE2-G was the preferred substrate, followed by PGF2α-G and PGD2-G. 
Remarkably, LYPLA2 displayed no activity against 2-AG or AEA. Thus, LYPLA2 is the 
first enzyme known to hydrolyze PG-Gs but not their endocannabinoid precursors. 
LYPLA2 is more active against PG-Gs than the two enzymes previously reported to 
exhibit PGE2-G hydrolase activity. LYPLA2’s catalytic activity for PGE2-G is 2 times 
and 52 times greater than those of CES1 and PPT1, respectively (99). Furthermore, 
unlike LYPLA2, CES1 and PPT1 are both more active against 2-AG than against PGE2-
G (98, 99, 171). Interestingly, neither CES1 nor PPT1 are present in any of the cancer 
cell lines used, demonstrating that the majority of PG-G hydrolytic activity in highly 
enzymatically active cells is LYPLA2. 
In human tissues, LYPLAs are widely distributed in multiple tissue types (193).  
Interestingly, LYPLA2 has a narrower range of lysophospholipid substrates than 
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LYPLA1. The latter enzyme, which is 60% identical to LYPLA2 in sequence, hydrolyzes 
a range of lysophospholipids; including lysophosphatidylcholine, 
lysophosphathidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, and 
lysophosphatidylserine.  Additionally, LYPLA1 displays acyl-protein thioesterase 
activity, and has the ability to remove the palmitate group from G protein α subunits 
(198). In contrast, LYPLA2 hydrolyzes only lysophosphatidylcholine and 
lysophosphathidylethanolamine (186, 187, 189), and exhibits no acyl-protein thioesterase 
activity. Interestingly, LYPLA2 hydrolyzes PGE2-G and other PG-Gs while LYPLA1 
does not. 
A previously reported inhibitor of LYPLA2 effectively reduced PGE2-G 
hydrolysis in vitro and increased endogenous levels of PGD2-G/E2-G in RAW264.7 cell 
and PGF2α-G in 1483 cell cultures. Optimization of this scaffold may increase the 
potency of inhibition of PG-G hydrolysis, and it will be interesting to attempt to identify 
molecules that inhibit PG-G hydrolysis without inhibiting lysophospholipid hydrolysis. 
Such compounds should be very useful probes of PG-G biology. Furthermore, 
differential production of PGF2α-G or PGD2-G/E2-G demonstrates that there may be a 
larger picture in relation to how PGH2 and PGH2-G interact with the prostaglandin 
synthases.  Further understanding into the relationship of prostaglandin precursors and 
prostaglandin synthases needs to be investigated. 
Figure 14 presents an updated metabolic pathway for endocannabinoid 
metabolism.   
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IV-14. LYPLA2 involvement in the hydrolysis of glycerol prostaglandins in the endocannabinoid metabolism network 
 
Figure 14: LYPLA2 involvement in the hydrolysis of glycerol prostaglandins in the 
endocannabinoid metabolism network. Abbreviations: cPLA2, cytosolic phospholipase 
A2; PLC, phospholipase C; DAGL, diacylglycerol lipase; COX, cyclooxygenase; CES, 
carboxyesterase; PTT1, Palmitoyl-protein thioesterase; LYPLA2, lysophospholipase A2. 
 
Once 2-AG is released from the membrane by the actions of phospholipase C 
(PLC) and diacylglycerol lipase (DAGL) (197, 199), 2-AG can either be hydrolyzed by 
MAGL, ABHD6, or ABHD12 (200, 201), to form AA, or oxidized by COX-2 to form 
PG-Gs. In human normal and cancer cells, PG-Gs can be hydrolyzed to form free acid 
prostaglandins by LYPLA2.  Inhibition of LYPLA2 can thereby cause an increase in the 
production of PG-Gs without having an effect on endocannabinoid hydrolysis.   
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Supplemental Information 
 
Supplemental Data 1. Activity-based protein profiling, multidimensional protein 
identification technology (ABPP-MuDPIT) analysis of serine hydrolases in human 
cancer cell lines (123, 156).  PGE2-G hydrolase activity was compared to known serine 
hydrolase inventories. 
Activity (ng PGE2/µg protein) LNCaP MCF7 231MFP PC3
Hydrolytic Acitity 34 52 65 70
Serine Hydrolases (Spectral Counting) LNCaP MCF7 231MFP PC3
 FASN Fatty acid synthase 1850 425 348 1324
MGLL monoglyceride lipase 11 7 37 54
FAAH2 Fatty-acid amide hydrolase 2 6 0 0 0
PREP prolyl endopeptidase 455 407 312 423
KIAA1363 (AADACL1 arylacetamide deacetylase-like 1) 58 1 26 373
APEH Acylamino-acid-releasing enzyme 571 145 165 642
PAFAH1B2 Platelet-activating factor acetylhydrolase IB subunit beta 19 84 105 22
PAFAH1B3 Platelet-activating factor acetylhydrolase IB subunit gamma 72 165 154 0
PAFAH2 Platelet-activating factor acetylhydrolase 2, cytoplasmic 19 9 5 22
ABHD2 Abhydrolase domain-containing protein 2 22 0 0 0
ABHD3 Abhydrolase domain-containing protein 3 2 0 0 7
ABHD4 Abhydrolase domain-containing protein 4 27 0 0 5
ABHD6 Abhydrolase domain-containing protein 6 55 0 1 62
ABHD10 Abhydrolase domain-containing protein 10 622 112 274 534
ABHD11 Abhydrolase domain-containing protein 11 258 169 64 136
ABHD12 Abhydrolase domain-containing protein 12 109 0 1 107
ABHD13 Abhydrolase domain-containing protein 13 2 0 0 1
LYPLA1 Acyl-protein thioesterase 1 81 92 42 21
LYPLA2 Acyl-protein thioesterase 2 31 95 97 138
LYPLAL1 Lysophospholipase-like protein 1 73 44 40 25
DPP4 Dipeptidyl peptidase 4 38 0 0 89
DPP7 similar to Dipeptidyl-peptidase 2 170 3 1 14
DPP8 Dipeptidyl peptidase 8 9 15 12 16
DPP9 Dipeptidyl peptidase 9 50 57 84 445
CES1 Liver carboxylesterase 1 0 0 0 0
CES2 carboxylesterase 2 18 11 12 8
CES3 esterase 3 2 0 0 0
PPT1 Palmitoyl-protein thioesterase 1 1 0 0 0
PPT2 palmitoyl-protein thioesterase 2 3 4 21 22
PRCP prolylcarboxypeptidase isoform 2 preproprotein 77 25 19 49
PREPL prolyl endopeptidase-like isoform C 63 33 30 98
RBBP9 Retinoblastoma-binding protein 9 9 23 29 10
PNPLA8 Patatin-like phospholipase domain-containing protein 8 15 0 0 11
PNPLA6 Neuropathy target esterase 46 0 1 211
PNPLA4 Patatin-like phospholipase domain-containing protein 4 49 3 6 42
SIAE Sialate O-acetylesterase 94 19 26 10
CTSA cathepsin A precursor 12 25 11 8
PPME1 Protein phosphatase methylesterase 1 63 20 17 48
Abhydrolase domain-containing protein FAM108A1 7 0 0 8
Abhydrolase domain-containing protein FAM108B1 12 0 0 31
PARL Presenilins-associated rhomboid-like protein 8 0 0 8
CPVL Probable serine carboxypeptidase 0 0 7 27
DAGLB Sn1-specific diacylglycerol lipase beta 6 0 0 20
PLAT Tissue-type plasminogen activator precursor 0 0 1 9
LIPA, highly similar to lysosomal acid lipase/cholesteryl ester hydrolase  0 0 5 0
HTRA1 Serine protease HTRA1 0 0 0 0
PGAP1 GPI inositol-deacylase 0 0 0 2
SCPEP Retinoid-inducible serine carboxypeptidase 121 0 0 47
PLAU urokinase plasminogen activator 0 0 0 1
PLA2G4A Cytosolic phospholipase A2 0 0 0 1
IAH1 Isoamyl acetate-hydrolyzing esterase 1 2 6 5 5
QRSL1 Glutaminyl-tRNA synthase-like protein 1 1 1 1 0
BCHE Cholinesterase precursor 10 0 0 0
BAT5 28 0 0 20
LACTB 2 0 0 2
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Supplemental Data 2:  LYPLA2 siRNA knockdown in PC3, MDA-MB-231, and 
LNCaP cells. (A) PGE2-G hydrolytic activity of cytosol obtained from PC3, MDA-MB-
231, and LNCaP control (scrambled) or LYPLA2-deficient (siRNA) cells. Western blot 
analysis of LYPLA2 in control (scrambled) and LYPLA2-depleted (siRNA) PC3 (B), 
MDA-MB-231 (C), or LNCaP (D) cells. β-actin Western blotting verified equaling 
protein loading (5 µg per lane). Data are presented as the mean ± S.D. of triplicate 
analyses.  **** indicates p <0.001.  ** indicates p <0.01. 
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Chapter V  
 
 
 
SUMMARY 
 
 
  
COX-2 catalyzes the oxidation of free fatty acids such as arachidonic acid during 
pathogenic states, including pain and inflammation.  This leads to the production of pro-
inflammatory lipid molecules known as prostaglandins. These prostaglandins mediate a 
wide array of physiological and pathophysiological effects, including pain, inflammation, 
and fever.  Additionally, COX-2 can oxidize the endocannabinoids, 2-arachidonoyl 
glycerol (2-AG) and arachidonylethanolamine (AEA), to form the prostaglandin 
derivatives, prostaglandin glycerol esters (PG-Gs) and prostaglandin ethanolamines (PG-
EA).  These prostaglandin derivatives have been shown to play unique roles on yet 
unidentified receptors throughout the body; eliciting pro-inflammatory responses, anti-
inflammatory responses, hyperalgesia and neurotoxicity.  
Though PG-G can elicit a wide array of biological responses in an in vitro setting, 
understanding in vivo effects of these lipid metabolites has been difficult due to 
hydrolytic instability.  It has been shown that PGE2-G is rapidly hydrolyzed in rat plasma 
post intravenous administration. This instability was attributed to the presence of plasma 
esterases that hydrolyze PG-Gs. Initially, the endocannabinoid hydrolyzing enzymes, 
FAAH and MAGL, were examined as potential PG-G hydrolyzing enzymes but kinetic 
analysis showed that neither enzyme efficiently hydrolysis. Inhibitor studies lead to the 
identification of CES1 and PPT1 as serine hydrolases capable of hydrolyzing both 2-G 
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and PG-Gs, though with both enzymes having higher affinity for 2-AG.  Multiple human 
cancer cells possess high activity levels for PG-G hydrolysis and do not express CES1 
and/or PPT1. The goal of my work was to identify the hydrolase responsible for PG-G 
hydrolysis in human cancer cell lines.   
Firstly, we developed a high-throughput analytical method in order to facilitate 
analysis during purification of the active enzyme. The most widely used methods for PG 
and PG-G analysis employ chromatographic separation followed by mass spectrometric 
analysis, which requires significant time for sample preparation and sequential 
chromatography. We developed a high-throughput, separation-free methodology based 
on MALDI mass spectrometry that allowed for the parallel analysis of prostaglandins and 
prostaglandin glycerol esters. Utilizing derivatization techniques with Girard’s reagent T 
we were able to incorporate a charged moiety into ketone-containing prostaglandins 
causing a dramatic increase in the signal-to-noise ratio relative to underivatized samples.  
This derivatization resulted in an increased dynamic range and improved linearity. 
Additionally, this method was adapted for high-throughput screening methods for 
enzymology and drug discovery.  
Initially, MDA-MB-231 cellular fractionation studies demonstrated that the 
protein of interest was a cytosolic protein, with no major activity present in the 
membrane.  Furthermore, because many of the lipid-hydrolyzing enzymes are serine 
hydrolases, we utilized a fluorophosphonate serine hydrolase inhibitor to verify that the 
unknown hydrolase was a member of the serine hydrolase superfamily. Understanding 
the cellular location and enzyme superfamily made purification simpler for two reasons: 
first, membrane protein purification requires the use of detergents, which can hinder 
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some forms of purification and second, because it allowed us to use very well developed 
ABPP techniques to identify the hydrolase. Utilizing protein purification techniques 
coupled with mass spectrometric proteomics, we ventured to identify the hydrolase 
responsible for PG-G hydrolysis in MDA-MB-231 cancer cells. Multiple purification 
steps led to the identification of three serine hydrolases as potential PG-G hydrolase 
targets; namely 6-phosphoglucolatonase (PGLS), dimethylarginine 
dimethylaminohydrolase 2 (DDAH2), and platelet activating factor acetylhydrolase 1β3 
subunit  (PAFAH1β3). All identified proteins were heterologously expressed in HEK293 
cells, with only PGLS demonstrating a minor increase in hydrolytic activity compared to 
untransfected cells.  Unfortunately, upon siRNA knockdown of PGLS in MDA-MB-231 
cancer cells, no change in hydrolytic activity was observed.  These results caused us to 
reevaluate how we went about identifying the unknown PG-G serine hydrolase.  
A data comparison between serine hydrolase inventories/activities and PG-G 
hydrolase activity was utilized to determine the serine hydrolase of interest.  By 
comparing PG-G hydrolytic activity across a number of human cancer cell types to serine 
hydrolase activity levels determined by activity-based protein profiling, we were able to 
identify the cytosolic lysophospholipid-metabolizing enzyme, lysophospholipase A2 
(LYPLA2), as the major hydrolase responsible for PG-G hydrolysis.  The importance of 
LYPLA2 in PGE2-G hydrolysis was confirmed by siRNA knockdown across various 
cancer cell types.  Heterologous expression of LYPLA2 in HEK293 cells also increased 
PGE2-G hydrolysis. The LYPLA2 isoform, lysophophospholipase A1 (LYPLA1), was 
also assessed for hydrolytic activity.  It was hypothesized that LYPLA1 may also play a 
role in PG-G hydrolysis because the enzyme shares 60% sequence homology with 
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LYPLA2 and also catalyzes the same lysophospholipid metabolism.  However, upon 
siRNA knockdown of LYPLA1 in MDA-MB-231 cancer cells, heterologous expression 
of LYPLA1 in HEK293 cells, or recombinant expression of LYPLA1 in E.coli, no 
change in PGE2-G hydrolytic activity was observed.  These results confirmed that 
LYPLA2 was the major serine hydrolase responsible for PG-G hydrolysis in highly 
hydrolytically active cell lines.   
Identification of LYPLA2 helped us understand why there was a significant 
decrease in hydrolytic activity during the MDA-MB-231 purification.  It has been 
reported that during purification of LYPLA2, steps must be taken in order to ensure the 
stability of the protein.  Addition of stabilizing agents such as 60-70% glycerol or 
exogenously added protein, such as cytochrome c, must be made in order to stabilize 
LYPLA2 during and after purification.  Additionally, work has shown that LYPLA2 is 
only stable at pH range 6 to 7.5. Since the Mono P column was run from pH range 7 to 4, 
LYPLA2 may have been destabilized/degraded during this step in the purification.   
Expression of LYPLA2 in E.coli led to the isolation and purification of active 
enzyme.  Substrate kinetics were determined with the relative activities against a series of 
PG-Gs being PGE2-G > PGF2α-G > PGD2-G. Interestingly, LYPLA2 did not hydrolyze 
the endocannabinoids, 2-AG or AEA.  Unlike CES1 and PPT1, LYPLA2 is the first PG-
G hydrolyzing enzyme that is not capable of hydrolyzing the endocannabinoids. LYPLA2 
has a narrower range of lysophospholipid substrates than LYPLA1, which hydrolyzes the 
majority of lysophospholipids, including lysophosphatidylcholine, 
lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, and 
lysophosphatidylserine. In contrast, LYPLA2 hydrolyzes only lysophosphatidylcholine 
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and lysophosphatidylethanolamine.  There is very little known about LYPLA2, 
particularly why this isoform has much greater specificity compared to LYPLA1. Further 
investigation is needed to understand what residues are important for LYPLA2 
specificity. Site-directed mutagenesis should be performed in order to identify these 
important residues.  Since LYPLA1 and LYPLA2 share 60% sequence homology and 
LYPLA1 has a crystal structure, selection of residues for mutation can be accomplished 
by comparing the LYPLA2 sequence to LYPLA1.   Based on the crystal structure of 
LYPLA1, determining what residues are different between the two enzymes within the 
active site will help explain substrate differences between LYPLA1 and LYPLA2. 
Finally, obtaining a crystal structure, as well as structures with both lysophospholipids 
and PG-Gs bounds, will also help elucidate important residues for binding. 
  Chemical inhibition of LYPLA2 in the RAW264.7 murine macrophage-like cell 
line and the 1483 human head-and-neck squamous cell carcinoma elicited an increase in 
PG-G production.  These were the first examples in cell culture of increases in 
endogenously produced PG-Gs following inhibitor treatment. Interestingly, in human 
cancer cells the predominant PG-G produced was PGF2α-G and not PGD2-G/E2-G. 
Differential production of PGF2α-G compared to PGD2-G/E2-G potentially demonstrates 
that there may be a relation between PGH2 and PGH2-G interactions with the 
prostaglandin synthases. Further investigations into the relationship of prostaglandin 
precursors and prostaglandin synthases needs to be undertaken. Moreover, cancer cells 
may need to hydrolyze PGF2α-G over other PG-Gs because they may be detrimental to 
the survival and growth of the cancer cells. Additional studies need to be conducted to 
understand the effects various PG-Gs play on cancer cell survival and growth. 
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Identification of LYPLA2 as a major PG-G hydrolase will enable modulation of 
its activity to evaluate its importance as a regulator of cell signaling by this unique class 
of bioactive lipids.  There are a number of different approaches that can be taken in order 
to investigate LYPLA2’s importance in vivo.  By having inhibitor compounds developed, 
and potentially expanded upon, we can further understand LYPLA2 and its role in living 
systems.  Additionally, genetic knockout of LYPLA2 may allow for in vivo increases in 
PG-G, which will expand our understanding of PG-G function in physiological and 
pathophysiological settings.  
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